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57 ABSTRACT 
A method of phosphate ester hydrolysis including incubat 
ing a solution of an aqueous phosphate ester with a metal 
lotexaphyrin complex under conditions and for a time suf 
ficient to hydrolyze the phosphate ester. The metal is a metal 
cation having catalytic activity for ester bond hydrolysis in 
aqueous solution. Phosphate ester substrates include nucleic 
acid such as RNA phosphoric anhydrides, phospholipids, 
and alkyl phosphate esters. 
28 Claims, 6 Drawing Sheets 
5'-EuTx-NH- (CH2) g-PO-CTC GGC CAT AGC GAA TGT TC-3' 
3'-pc C ACU GUAGAA GAG CCG GUA UCG CUU ACA AG-5 
5'-DyTxNH-(CH2)6-PO4-CAT CTG TGA GCC GGG TGT TG-3' 
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SEQ. ID. NO. 7 
5'-AT AGC G A TGT TC-3' 
3'-C ACU GUA GAA GAGCCG GUA UCG C U ACA AG-5' 
CDy) -\f SEQ. D. NO. 8 
SEQ. ID.N.O. 9 
5'-AT AGC G A TGT-3' 
3'-C ACU GUA GAA GAGCCG GUA UCG R ACA AG-5 
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METHOD OF PHOSPHATE ESTER 
HYDROLYSS 
This application is a continuation of co-pending appli 
cation U.S. Ser. No. 081485.581 filed Jun. 7, 1995 now 
abandoned, which is a continuation-in-part of application 
U.S. Ser. No. 08/452.261, filed May 26, 1995 now 
abandoned, which is a continuation of International appli 
cation No. PCT/US94/06284 designating the United States, 
filed Jun. 9, 1994, which is a continuation-in-part of appli 
cation U.S. Ser. No. 08/227.370, filed Apr. 14, 1994, now 
U.S. Pat. No. 5,559,207, which is a continuation-in-part of 
application U.S. Ser. No. 08/075,123, filed Jun. 6, 1993, now 
abandoned which is a continuation-in-part of application 
U.S. Ser. No. 07/822,964, filed Jan. 1, 1992 now U.S. Pat. 
No. 5.252,720. 
The government has certain rights in the present inven 
tion pursuant to National Institutes of Health, National 
Cancer Institute SBIR Grant No. 1 R43 CA67728-01. 
FIELD OF THE INVENTION 
The present invention relates to catalysts for the cleavage 
of ester bonds, and particularly phosphate ester bonds, 
including those related to a biological system. 
BACKGROUND OF THE INVENTION 
Many divalent and trivalent metal salts have been shown 
to promote the hydrolysis of phosphate ester bonds. 
Komiyama et al. (1992) reported the hydrolysis of adenylyl 
(3'-5')adenosine and uridyl(3'-5')uridine at pH 8.0, 30° C. by 
rare earth metal(II) ions. A cerium(III) hydroxide cluster 
has been reported to hydrolyze 3',5'-cyclic adenosine mono 
phosphate (Sumaoka, et al. 1992). Browne and Bruice 
(1992) reported the hydrolysis of bis(8-hydroxyquinoline) 
phosphate in the presence of divalent cations. However, in 
order to convey a degree of specificity to catalysis by the 
metal ion, complexes of metals with various ligands have 
been studied. The ligand may serve a number of roles in 
catalysis, including modulation of catalytic efficiency and 
maintenance of the metalion in solution, while also allowing 
for coupling of reagents having a binding specificity for a 
desired substrate. 
Ligands complexing metal ions for use in the hydrolysis 
of phosphate ester bonds include: tris(aminopropyl)amine 
(trpn), 14.7.10-tetraazacyclododecane (cyclen), tris(2- 
aminoethyl)amine (tren), triethylenetetramine (trien), tetra 
ethylenepentamine (tetren), bipyridine conjugates. 
imidazole, cyclodextrin derivatives, lysine, terpyridine 
(trpy), 1,2-diaminoethane, a bis(diaquo) complex, "metal 
lomicelles" and a phenanthrolinepolyamine tridentate com 
plex (Basile et al. 1987; Menger et al. 1987; Chung et al. 
1990; Hendry and Sargeson, 1989; Shelton and Morrow, 
1991; Ranganathan et al. 1993; Breslow and Huang, 1991; 
Modak et al. 1991; Kim and Chin, 1992; Chin et al. 1989; 
Chin and Banaszczyk, 1989a,b; Chin and Zou, 1987). 
In order for a metal complex to function catalytically in 
vivo, the complex should not release bound metal ion. 
Morrow et al. (1992) have studied the cleavage of RNA by 
a lanthanide(III) hexamine Schiff-base (HAM) macrocyclic 
complex. Cleavage of the dinucleotide adenylyl-3',5'uridine 
3'-monophosphate (App) or of oligomers of adenylic acid 
(A12-A18) was reported at 37° C. after 4 hours by several 
lanthanide complexes. Other hexadentate ligands such as 
EDTA formed lanthanide(III) complexes that were com 
pletely inactive in RNA cleavage under similar conditions. 












reported to change dramatically throughout the lanthanide 
series. These complexes have some serious disadvantages, 
including high toxicity of the HAM ligand, weak coordina 
tion and dissociation of the lanthanide metals. Further, the 
ligand cannot be easily modified which precludes the gen 
eration of derivatives with substrate specificity. 
Given the limitations of the HAM complex, it is clear that 
the development of new macrocycles capable of chelating 
lanthanide metals and forming stable complexes which are 
able to cleave RNA would be of utility. 
Texaphyrins are aromatic pentadentate macrocyclic 
"expanded porphyrins" which have been found to be useful 
as MRI contrast agents, as radiation sensitizers and in 
photodynamic therapy (PDT). Texaphyrin is considered as 
being an aromatic benzannulene containing 227t-electron 
delocalization pathways. See, e.g., Sessler, J. L. et al. 
Accounts of Chemical Research, 1994. 27:43. Texaphyrins 
and water-soluble texaphyrins and methods of preparation 
have been described in U.S. Pat. Nos. 4935,498; 5.252,720; 
5.256399; 5.272,142; and 5.292414; and in International 
application Ser. No. PCT/US95/01996; all of which are 
incorporated herein by reference. 
Antisense therapeutics are designed to bind to comple 
mentary RNA targets by mimicking the DNA template used 
in their production. Complexation to an RNA target, itself, 
is usually insufficient to inhibit protein synthesis by the 
RNA, as cellular factors such as ribosomes compete effec 
tively for the RNA. Nonetheless, the desired biological 
effect has often been observed due to the activity of the 
enzyme RNase H. This enzyme catalyzes the degradation of 
RNA present as a heteroduplex (RNA that is bound by 
single-stranded DNA or by an oligonucleotide-based thera 
peutic which is sufficiently similar in structure to DNA). 
Although operative in many cells, this mechanism has the 
drawback that it relies on participation of an enzyme to 
activate the RNA-oligonucleotide heteroduplexes. Also, as 
RNase H is a nuclear enzyme, this mechanism of action is 
presumably confined to this cellular compartment. 
An important consideration in the development of anti 
sense agents is their delivery to the target cells and the 
genetic material. Due to the presence of enzymes which 
degrade them, RNA and DNA are not sufficiently stable to 
be administered in their native forms. Limited penetration of 
these charged oligomeric materials into cells or nuclei also 
presents a serious challenge to this approach. For these 
reasons, a large number of structural analogs, such as the 
phosphorothioates and 2'-O-methyl RNA, have been inves 
tigated as antisense agents. Whereas such analogs often 
overcome the problems of instability or poor cellular uptake, 
the chemical modifications usually eliminate the ability of 
the antisense agent to elicit RNase H activity. Phospho 
rothioate analogs are noteworthy in that they display high 
stability and retain substrate activity for RNase H. The 
phosphorothioates are currently being evaluated in Phase III 
clinical trials for treatment of cytomegalovirus retinitis in 
AIDS patients. However, because they rely on the RNase H 
enzyme for their activity, little or no structural modifications 
can be made to these analogs, thus limiting their versatility. 
Another approach to antisense therapy is based on the 
application of ribozyme chemistry. Ribozymes are enzymes 
made of RNA that are able to hydrolytically cleave comple 
mentary RNA substrates in a catalytic fashion. Originally 
discovered as sequences of RNA that catalyze their own 
removal during nuclear processing, modified forms of these 
enzymes are being developed as antisense agents. These 
tailored ribozymes cannot be administered as therapeutics, 
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however, due to their size and structure and the inherent 
instability of RNA. 
In view of the limitations of the natural ribozyme and 
oligonucleotide analog-based antisense approaches, it would 
be desirable to develop a therapeutic exhibiting nuclease 
stability, strength of hybridization and cell penetrability 
without regard for its ability to act as a substrate for 
endogenous RNase H. 
SUMMARY OF THE INVENTION 
The present invention seeks to solve the problems found 
in the prior art by providing metallotexaphyrin complexes 
and metallotexaphyrin complex-conjugates for phosphate 
ester hydrolysis that provide stable complexation for an 
otherwise toxic metallic cation, specificity for targeted sites 
in a therapeutic application, and sufficient nontoxicity for in 
vivo use. 
The present invention involves the discovery that metal 
lotexaphyrin complexes catalyze the hydrolysis of phos 
phate ester linkages. Texaphyrins are unique molecules in 
that they complex the metal in a very stable molecule but 
allow access to the metal coordination sites, thus preserving 
the metal's reactivity and its ability to hydrolyze phospho 
ester bonds. Furthermore, the texaphyrin molecule allows 
for derivatization for various biological applications. The 
texaphyrin complex is far less toxic and far more stable than 
the HAM complex as well. 
Thus, the present invention provides a method of phos 
phate ester hydrolysis. The method comprises contacting a 
phosphate ester, in aqueous solution, with a metallotexaphy 
rin complex having catalytic activity for phosphate ester 
bond hydrolysis, the contact being under conditions and for 
a time sufficient to hydrolyze the phosphate ester, 
A metallotexaphyrin complex as used herein is an aro 
matic pentadentate expanded porphyrin analog metal com 
plex with appended functional groups. Such pendant groups 
may enhance solubility or biolocalization or may provide 
coupling sites for site-directed molecules or catalytic 
groups. 
It will be apparent to one of skill in the art in light of the 
present disclosure that a variety of phosphate ester linkages 
may be cleaved by the molecules of the present invention. 
Exemplary ester linkages cleaved by the molecules of the 
present invention include phosphate monoester and diester 
linkages, especially physiologically important phosphate 
linkages present in nucleic acids such as RNA; 
p-nitrophenylphosphate ester, a widely used substrate for 
assays; phosphoric anhydrides, including important media 
tors of metabolism such as nucleotides ATP, ADP, AMP. 
cAMP, UDP, NADH, NADPH, FAD or FADH, for 
example; and phospholipids such as phosphatidyl choline 
and sphingomyelin that are important in nerve and brain 
functions. 
Metallotexaphyrin complexes possess inherent biolocal 
ization. Additionally, in one embodiment of the present 
invention, the metallotexaphyrin complexes are further 
coupled to site-directed molecules to form conjugates for 
targeted in vivo delivery. "Specificity for targeted sites" 
means that upon contacting the metallotexaphyrin complex 
conjugate with the targeted site, for example under physi 
ological conditions of ionic strength, temperature, pH and 
the like, specific binding will occur. The interaction may 
occur due to specific electrostatic, hydrophobic, entropic or 
other interaction of certain residues of the conjugate with 
specific nucleotide, amino acid or glycolytic residues of the 











tive to promote the interaction. In the present invention, this 
interaction will allow cleavage of an ester linkage that is in 
the vicinity of the specific binding. 
Another embodiment of the present invention is a method 
of phosphate ester hydrolysis comprising contacting a phos 
phate ester, in aqueous solution, with a metallotexaphyrin 
complex linked to a sapphyrin. Sapphyrins have binding 
specificity for phosphate esters. The contact is under con 
ditions and for a time sufficient to hydrolyze the phosphate 
ester. 
Another embodiment of the present invention is a method 
for targeted intracellular RNA hydrolysis. The method com 
prises the introduction into a cell of a metallotexaphyrin 
complex coupled to an oligonucleotide having complemen 
tary binding affinity for a targeted RNA, whereby hydrolysis 
of the targeted RNA is catalyzed by the metallotexaphyrin 
complex. The RNA may be, for example, viral RNA 
(including retroviral RNA), messenger RNA (mRNA), ribo 
somal RNA, RNA cofactors, transfer RNA. Small nuclear 
RNA, and small cytoplasmic RNA, thereby providing a 
multifactorial approach to eliminating diseased, cancerous 
or other unwanted cells or tissues. A site of desired hydroly 
sis may be a position novel to undesired organisms in terms 
of health care. A site of desired hydrolysis may be an mRNA 
encoding a product deleterious to the host or may be a 
normal mRNA that is deleterious in some way. The mRNA 
may be transcribed from an oncogene or it may encode a 
growth factor, for example. 
Texaphyrins are ideal for intracellular transport and cell 
delivery of a large variety of monomeric and oligomeric 
nucleotide species and their derivatives, including RNA, 
DNA, anti-viral agents and antisense agents. Texaphyrins 
exhibit the ability to cross cellular membranes. When the 
texaphyrin is complexed or conjugated to a second 
molecule, the second molecule, in the present case an 
oligonucleotide, will be transported across the membrane 
and into the cell together with the texaphyrin. 
A further embodiment of the invention is a method of 
modulating the activity of an RNA, comprising contacting 
the RNA with a metallotexaphyrin complex either directly or 
in cells, tissues or bodily fluids containing the RNA, under 
conditions and for a time sufficient to hydrolyze the RNA. 
The metallotexaphyrin complex is selected from those that 
exhibit catalytic activity for RNA hydrolysis, and the com 
plex is present in an amount effective to modulate the RNA 
activity or function. By "modulating the activity of an RNA” 
is meant that the metallotexaphyrin complex interferes with 
or otherwise diminishes the RNA activity or function. A 
preferred function to be modulated is the export of mRNA 
from cell nuclei. Another is splicing of the mRNA. Yet 
another function is translation of the mRNA into a protein. 
thereby modulating the production of a protein by an organ 
ism. Generally, the mRNA selected is cell-, tissue- or 
disease-specific. In a presently preferred embodiment, the 
metallotexaphyrin complex is coupled to an oligonucleotide 
having complementary binding affinity for the RNA whose 
activity is to be modulated. 
A method for inhibiting the expression of a gene in an 
animal comprising the administration to the animal of a 
metallotexaphyrin complex-oligonucleotide conjugate is a 
further embodiment of the present invention. The oligo 
nucleotide may have complementary binding affinity for 
messenger RNA transcribed from said gene or may be 
complementary to either strand of the DNA surrounding the 
gene or encoding the gene. The gene may be an oncogene or 
it may encode a growth factor, for example. A further 
5,763,172 
5 
embodiment of the present invention is a method for inhib 
iting the expression of a gene in a particular tissue of an 
animal comprising administering to the animal a 
metallotexaphyrin-oligonucleotide conjugate having speci 
ficity for the tissue. The metallotexaphyrin complex 
conjugate may have appended an oligonucleotide comple 
mentary to the target gene and a further appended tissue 
specific molecule like estradiol, for example, or an antibody 
directed for said tissue or a peptide having affinity for a 
biological receptor on said tissue. 
A further embodiment of the present invention is a 
texaphyrin metal complex-conjugate wherein two or more 
separate metallotexaphyrin complexes are attached to an 
oligonucleotide, one at the 3' and one at the 5' end, and/or 
one or more at an internal residue, and/or two complexes at 
one end, e.g. a "dimer' of two metallotexaphyrins at the 5' 
end of the oligonucleotide. The metal ion of each of the 
texaphyrin complexes may be the same or it may be differ 
ent. Use of a dual metallotexaphyrin complex-conjugate 
should effect the hydrolysis of RNA with increased effi 
ciency due to the concerted activity of the metal complexes. 
For diagnosis and treatment purposes, the administration of 
such a conjugate with one texaphyrin complex having an 
ester bond-hydrolyzing metal species and the other having a 
paramagnetic species would allow binding, imaging and 
hydrolysis, all effected by one conjugate. In this case, 
binding is effected by the oligonucleotide, imaging is 
accomplished by MRI due to the presence of the paramag 
netic metalion and hydrolysis is accomplished by the ester 
bond-hydrolyzing metal species. Therefore, the biodistribu 
tion and cellular penetration of the conjugate may be deter 
mined. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the recombinant plasmid from which P 
labelled 2000 base pair RNA transcripts were made for the 
RNA hydrolysis experiments of Example 2. R1=EcoRI, 
MCS=multi-cloning sequence. 
FIG. 2 shows europium(III) texaphyrin (EuTx) DNA 
conjugates of Example 3, dysprosium(III) texaphyrin 
(DyTx) conjugates of Example 4, oligonucleotides conju 
gated at the 3' end to texaphyrin, and dual conjugates, i.e. 
oligonucleotides having a texaphyrin conjugated to the 5' 
and to the 3' ends. Oligonucleotides are written in a 5'-3' 
direction. 
FIG.3 shows a schematic representation of cleavage of an 
RNA 31-mer by EuTx-DNA conjugate and of an RNA 
36-mer by DyTx-DNA conjugate; the arrows show sites of 
metal-catalyzed hydrolysis. 
FIGS. 4A and 4B show examples of the oligonucleotide 
conjugate having a one-base deletion and, therefore, causing 
the substrate to have a one-base loop with enhanced sus 
ceptibility to hydrolysis. 
FIG. 5 shows the use of a set of metallotexaphyrin 
complex-oligonucleotide conjugates targeted for the same 
hydrolysis site on the RNA template. 
FIGS. 6 and 7 show the inhibition of cell proliferation by 
DyTx-oligonucleotide conjugates. FIG. 6 is a comparison of 
a sequence-specific DyTx-oligonucleotide conjugate with its 
non-conjugated oligonucleotide analog. FIG.7 is a compari 
son of the sequence-specific DyTx-oligonucleotide conju 
gate with a sequence-nonspecific DyTx-oligonucleotide 
conjugate. 
DEALED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The present invention involves the use of metallotexa 











More particularly, the invention involves the cleavage of 
phosphate ester bonds of a diester, a monoester, an RNA 
substrate, and the like, using a metal complex of a texaphy 
rin. 
The texaphyrins have now been shown by the inventors to 
catalyze the hydrolysis of phosphate ester bonds. More 
specifically, a metallotexaphyrin complex or a metallotexa 
phyrin complex-conjugate having catalytic activity for ester 
bond hydrolysis is added to an aqueous solution containing 
a phosphate ester and is incubated for a time and under 
conditions sufficient to hydrolyze the phosphate ester bond. 
Such conditions are known to those of skill in the art or can 
be determined by such persons without undue experimen 
tation. It has been found that such conditions include physi 
ologic conditions. This is especially useful when the texa 
phyrin complexes are used in vivo as a treatment procedure 
to hydrolyze RNA. for example. 
The phosphate ester can be contacted with the metallo 
texaphyrin complex or complex-oligonucleotide conjugate 
either directly, such as would be the case in certain diag 
nostic applications, or in cells, tissues or bodily fluids 
containing the phosphate ester. 
Potential particular applications for the process of this 
invention include the specific cleavage and possible subse 
quent recombination of RNA; destruction of viral or bacte 
rial RNA; digestion of cell membrane components such as 
phosphatidyl cholines and sphingomyelin; disruption of the 
transfer of free energy in cells by hydrolyzing ATP. ADP, 
NADH, NADPH, FAD or FADH; treatment of liver dis 
eases by preventing the formation of glycogen; regulation of 
hormones by hydrolysis of cAMP; hydrolysis of mutagenic 
and carcinogenic di- and trialkylphosphates commonly used 
as solvents; and the detoxification of phosphate ester nerve 
gases and insecticides by hydrolysis of phosphate ester 
bonds. In a presently preferred embodiment, the phosphate 
ester is a nucleic acid ester. 
The aqueous phosphate ester solution may be a solution or 
a suspension of nucleic acid, for example, a solution or 
suspension of RNA or DNA. The aqueous phosphate ester 
solution may be the intracellular environment containing the 
target RNA or DNA, or it may be or bodily fluids. The 
aqueous solution may, in addition, be water from a stream, 
river or lake, for example, or effluent that contains a physi 
ologically or environmentally undesirable phosphate ester 
containing compound. RNA is more preferably hydrolyzed 
than DNA by a factor of about 10'. When the phosphate 
ester is RNA, the metal is preferably a lanthanide or a 
lanthanoid metal cation, more preferably Tb(III) or Dy(III). 
In the practice of the present invention, the texaphyrin 
macrocycle to be complexed to the metalion may be chosen 
from any texaphyrin molecule, including those now known 
and disclosed in the U.S. patents and patent applications 
incorporated by reference herein. Representatives of metal 
lotexaphyrin complexes included within the present inven 
tion are encompassed within the following structure I: 
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In this metallotexaphyrin complex, M is a divalent or a 
trivalent metal cation having catalytic activity for phosphate 
ester bond hydrolysis in aqueous solution. 
R-R. R. and Rs are independently hydrogen, halide. 
hydroxyl, alkyl, aryl. haloalkyl, nitro, formyl, acyl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, saccharide. 
carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, 
aminoalkyl, sulfonatoalkyl, amidealkyl, aryl, a site-directed 
molecule, a catalytic group, or a couple to a site-directed 
molecule or to a catalytic group. 
R and R are independently selected from the groups of 
R-R. R. and Rs with the proviso that the halide is other 
than iodide and the haloalkyl is other than iodoalkyl. 
Rs and Ro-R2 are independently hydrogen, alkyl, aryl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, carboxyalkyl, 
carboxyamidealkyl or a couple to a saccharide, to a site 
directed molecule or to a catalytic group. 
Z will typically be less than or equal to 5. In the context 
of the basic macrocycle with a divalent or trivalent metal 
cation, Z is 1 or 2; however, one skilled in the art in light of 
the present disclosure would realize that the complexes 
described in the present invention may have one or more 
additional ligands providing charge neutralization and/or 
coordinative saturation to the metal ion. Such ligands 
include chloride, nitrate, acetate, and hydroxide, among 
others. The value of Z would also be altered due to charges 
present on, for example, a covalently attached site-directed 
molecule, such as negative charges of the phosphate groups 
on an oligonucleotide. 
In a preferred embodiment, at least one of R-R is a 
site-directed molecule or is a couple to a site-directed 
molecule. For bulky R groups on the benzene ring portion of 
the molecule such as antibodies, peptides or 
oligonucleotides, one skilled in the art would realize that 
derivatization at one position on the benzene portion is more 
preferred. 
"Alkyl” means alkyl groups, straight, branched or as 
cyclic isomers, with generally one to fifty, preferably one to 
thirty, more preferably one to ten, carbon atoms. 
"Alkenyl" means alkenyl groups, straight, branched or as 
cyclic isomers, with generally two to fifty, preferably two to 
thirty, more preferably two to ten, carbon atoms, and with 
one to five or more double bonds, preferably one to five, 
more preferably one to three double bonds. 
"Hydroxyalkyl” means alcohols of alkyl groups. Pre 
ferred are hydroxyalkyl groups having one to twenty, more 
preferably one to ten, hydroxyls. "Hydroxyalkyl" is meant to 
include glycols and polyglycols; diols of alkyls, with diols 
of Coalkyls being preferred, and diols of Calkyls being 










glycol and polybutylene glycol as well as polyalkylene 
glycols containing combinations of ethylene, propylene and 
butylene. 
"Oxyalkyl" means alkyl groups as herein described with 
oxygen atoms, including ether or ester linkages. The number 
of repeating oxyalkyls within a substituent may be up to 200. 
preferably from 1 to 20, more preferably from 1 to 7, and 
most preferably is 2-3. 
"Hydroxyalkoxy" means alkyl groups as described herein 
having ether or ester linkages, as well as hydroxyl groups. 
substituted hydroxyl groups, carboxyl groups, substituted 
carboxyl groups or the like. 
"Carboxy" groups include carboxylic acids of the alkyls 
described herein as well as aryl carboxylic acids such as 
benzoic acid. "Carboxyalkyl" means alkyl groups having 
hydroxyl groups, carboxyl or amide substituted ethers, ester 
linkages, tertiary amide linkages removed from the ether or 
the like. Representative examples of "carboxyamides" 
include primary carboxyamides (CONH2), and secondary 
(CONHR') and tertiary (CONR'R") carboxyamides where 
each of R' and R" is a functional group as described herein. 
"Carboxyamidealkyl" means alkyl groups with hydroxyl 
groups, secondary or tertiary amide linkages or the like. 
Representatives of useful amines include a primary, sec 
ondary or tertiary amine of an alkyl as described herein 
above. 
"Aryl” may be a phenyl group, unsubstituted or substi 
tuted with a nitro, carboxy, sulfonic acid, hydroxy, oxyalkyl, 
or halide. 
The term "saccharide' includes oxidized, reduced or 
substituted saccharide; hexoses such as D-glucose, 
D-mannose or D-galactose; pentoses such as D-ribose or 
D-arabinose; ketoses such as D-ribulose or D-fructose; 
disaccharides such as sucrose, lactose, or maltose; deriva 
tives such as acetals, amines, and phosphorylated sugars; 
oligosaccharides; as well as open chain forms of various 
sugars, and the like. Examples of amine-derivatized sugars 
are galactosamine, glucosamine, and sialic acid. 
"Carboxyamidealkyl" means alkyl groups with secondary 
or tertiary amide linkages or the like. "Carboxyalkyl" means 
alkyl groups having hydroxyl groups, carboxyl or amide 
substituted ethers, ester linkages, tertiary amide linkages 
removed from the ether, or the like. 
For the above-described texaphyrins, hydroxyalkoxy may 
be alkyl having independently hydroxy substituents and 
ether branches or may be CH12OO, or OCo 
H2OO, where n is a positive integer from 1 to 10, 
x is zero or a positive integer less than or equal to n, and y 
is zero or a positive integer less than or equal to (2n+1)-2x). 
The hydroxyalkoxy or saccharide may be CH 
OR OCH-OR or (CH2)COR where n is a 
positive integer from 1 to 10, y is Zero or a positive integer 
less than (2n+1)-q), q is zero or a positive integer less than 
or equal to 2n+1, and R is independently H. alkyl, 
hydroxyalkyl, saccharide, C-H 1-2.O.O. 
O2CCon-Hicom 1-2O.O. or N(R)OCCon-Ho-1-2) 
OO. In this case, m is a positive integer from 1 to 10, w 
is zero or a positive integer less than or equal to m, Z is zero 
or a positive integer less than or equal to ((2m+1)-2w), and 
R is H, alkyl, hydroxyalkyl, or CHOR, where m 
is a positive integer from 1 to 10, Z is zero or a positive 
integer less than ((2m+1)-r), r is zero or a positive integer 
less than or equal to 2m+1, and R is independently H. alkyl, 
hydroxyalkyl, or saccharide. 
Carboxyamidealkyl may be alkyl having secondary or 
tertiary amide linkages or (CH2)CONHR'. O(CH), 
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CONHR'. (CH2)CONCR), or O(CH),CONOR) where n 
is a positive integer from 1 to 10, and R is independently 
H. alkyl hydroxyalkyl Saccharide, CH2-12 
OO. OCC m-w) ((2m+1)-2w Ow s 
N(R6cC.-H...-6.O. or a site-directed mol 
ecule or catalytic group. In this case, m is a positive integer 
from 1 to 10, w is zero or a positive integer less than or equal 
to m, Z is zero or a positive integer less than or equal to 
((2m+1)-2w), and R is H, alkyl, hydroxyalkyl, or 
CH (2n+1)-O-R- In this case, m is a positive integer from 
1 to 10, Z is zero or a positive integer less than ((2m+1)-r), 
ris Zero or a positive integer less than or equal to 2m+1, and 
R is independently H, alkyl hydroxyalkylor saccharide. In 
a preferred embodiment, R is an oligonucleotide. 
Carboxyalkyl may be alkyl having a carboxyl substituted 
ether, an amide substituted ether or a tertiary amide removed 
from an ether or CH2O2. or OCH (21 OR where n is a positive integer from 1 to 10; y is zero or a 
positive integer less than (2n+1)-q), q is zero or a positive 
integer less than or equal to 2n+1, and R is (CH),CO.R. 
(CH),CONHR (CH),CON(R) or a site-directed mol 
ecule or catalytic group. In this case. n is a positive integer 
from 1 to 10, Ris independently H, alkyl hydroxyalkyl, 
Saccharide, Com-e Hot 2n+1)-2. Owoss 
9:CCo-Heon-1-2O.O. of N(ROCCo-Ho-1-2) 
OO. In this case. m is a positive integer from to 10, w 
is Zero or a positive integer less than or equal to m z is zero 
or a positive integer less than or equal to ((2m+1)-2w), and 
R is H. alkyl, hydroxyalkyl, or CHOR. In this 
case, m is a positive integer from 1 to 10, z is zero or a 
positive integer less than ((2m+1)-r), r is zero or a positive 
integer less than or equal to 2m+1, and R is independently 
H, alkyl hydroxyalkyl, or saccharide. In a preferred 
embodiment, R is an oligonucleotide. 
Hydrolytic cleavage of phosphate ester bonds, and par 
ticularly of RNA, by texaphyrin-metal complexes may be 
enhanced by additional catalytic groups appended to the 
texaphyrin-metal complex or to a texaphyrin complex-site 
directed molecule conjugate. The term "catalytic group” 
means a chemical functional group that assists catalysis by 
acting as a general acid, Bronsted acid, general base, 
Bronsted base, nucleophile, or any other means by which the 
activation barrier to reaction is lowered or the ground state 
energy of the substrate is increased. Exemplary catalytic 
groups contemplated include, but are not limited to, imida 
Zole; guanidine; substituted saccharides such as 
D-glucosamine, D-mannosamine, D-galactosamine, 
D-glucanine and the like; amino acids such as L-histidine 
and L-arginine; derivatives of amino acids such as hista 
mine; polymers of amino acids such as poly-L-lysine, 
(LysAla) (LysLeuAla), where n is from 1-30 or preferably 
1-10 or more preferably 2-7 and the like; derivatives 
thereof; and metallotexaphyrin complexes. The term 
"appended to the texaphyrin complex-site directed molecule 
conjugate” means that the catalytic groups are attached 
either directly to the metallotexaphyrin complex or to the 
texaphyrin complex via a linker or couple of variable length, 
or are attached to the site-directed molecule portion of a 
texaphyrin complex-conjugate either with or without a 
linker or couple of variable length. 
Exemplary site-directed molecules useful herein include, 
but are not limited to, polydeoxyribonucleotides; oligode 
Oxyribonucleotides; polyribonucleotide analogs; oligoribo 
nucleotide analogs; polyamides; molecules having affinity 
for a biological receptor, such as peptides, enzyme 
inhibitors, and proteins such as antibodies; steroids and 
steroid derivatives; hormones such as estradiol or histamine, 
and hormone mimics such as morphine; and further macro 
cycles such as sapphyrins and rubyrins. 
The oligonucleotides may be derivatized at the bases, the 











the backbone to promote in vivo stability. Modifications of 
the phosphate groups are preferred in one embodiment since 
phosphate linkages are sensitive to nuclease activity. Pres 
ently preferred derivatives are the methylphosphonates, 
phosphotriesters, phosphorothioates, and phosphoramidates. 
Additionally, the phosphate linkages may be completely 
substituted with non-phosphate linkages such as amide 
linkages. Appendages to the ends of the oligonucleotide 
chains also provide exonuclease resistance. Sugar modifi 
cations may include groups, such as halo, alkyl, alkenyl or 
alkoxy groups, attached to an oxygen of a ribose moiety in 
a ribonucleotide. In a preferred embodiment, the group will 
be attached to the 2' oxygen of the ribose. In particular, 
halogen moieties such as fluoro may be used. The alkoxy 
group may be methoxy, ethoxy or propoxy. The alkenyl 
group is preferably allyl. The alkyl group is preferably a 
methyl group and the methyl group is attached to the 2' 
oxygen of the ribose. Other alkyl groups may be ethyl or 
propyl. 
It is understood that the terms "nucleotide", "polynucle 
otide" and "oligonucleotide", as used herein and in the 
appended claims, refer to both naturally-occurring and syn 
thetic nucleotides, poly- and oligonucleotides and to analogs 
and derivatives thereof such as methylphosphonates, 
phosphotriesters, phosphorothioates and phosphoramidates 
and the like. Deoxyribonucleotides, deoxyribonucleotide 
analogs and ribonucleotide analogs are contemplated as 
site-directed molecules in the present invention. 
The term "metallotexaphyrin-oligonucleotide conjugate" 
means that an oligonucleotide is attached to the texaphyrin 
in a 5' or a 3" linkage, or in both types of linkages to allow 
the texaphyrin to be an internal residue in the conjugate. It 
can also refer to a texaphyrin that is linked to an internal base 
of the oligonucleotide. The oligonucleotide or other site 
directed molecule may be attached either directly to the 
texaphyrin or to the texaphyrin via a linker or a couple of 
variable length. During catalysis, for example, the texaphy 
rin portion of a texaphyrin-metal complex-oligonucleotide 
conjugate is placed in the vicinity of the substrate upon 
binding of the oligonucelotide to the targeted nucleic acid 
substrate. 
A conjugate group having site specificity or catalytic 
activity may be covalently coupled to a texaphyrin directly 
on the macrocycle ring or through various couples. A couple 
may be described as a linker, i.e. the covalent product 
formed by reaction of a reactive group designed to attach 
covalently another molecule at a distance from the texaphy 
rin macrocycle. Exemplary linkers or couples are amides, 
amine, thiol, thioether, ether, or phosphate covalent bonds as 
described in the examples for attachment of oligonucle 
otides. In preferred embodiments, conjugates and appended 
groups are covalently bonded to the texaphyrin via a carbon 
carbon, a carbon-nitrogen, a carbon-sulfur, or a carbon 
oxygen bond, more preferred being a carbon-oxygen or a 
carbon-nitrogen bond. 
In an embodiment of the present invention, M may be a 
divalent metal cation selected from the group consisting of 
Ca,Mn. Co°. Ni, Zn, Cd'?. Hg ?, Fet. Smand 
UO, or a trivalent metal cation selected from the grou 
consisting of Mn. Co., Ni, Fe", Ho", Ce", Y, In, 
Prt3, Nd, Sm, Eu. Gd, Tb3, Dy", Ert, Tm, 
Yb". Lu". La", and U. In particular, the metal may be 
La(III), Nd(III), Sm(III), Gd(III), TmIII), or Lu(III), or 
preferably, Y(III), Tb(III), Eu(III) or Dy(III). 
In presently preferred texaphyrins, R is hydroxyalkyl and 
R2, Ra and R are alkyl. Alternatively, R may be a site 
directed molecule or a couple to a site-directed molecule, 
preferably an oligonucleotide or a couple to an oligonucle 
otide. In a further presently preferred texaphyrin. R is 
CHCH or (CH2)CHOH. R. and R are CHCH. R. is 
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CH, and R and Rs are OCHCHCH-OH or R, and Rs are 
O(CHCHO),CHCHOR where t is 0-200, preferably 
2-100, and R is Hor CH. Alternatively. R is a site-directed 
molecule or a couple thereto, preferably an oligonucleotide 
or a couple thereto, more preferably O(CH2)CO 
oligonucleotide where n is 1-7 and preferably 1-3; and Rs 
is H, CH or OCH In a further presently preferred 
embodiment, R is CHCH or (CH2)CHOH. R. and R. 
are CHCH. R. is CHR, is O(CHCHO)CHCHOR 
where t is 0-200, preferably 2-100, and R is H or CH, and 
R is a site-directed molecule or a couple thereto, preferably 
an oligonucleotide or a couple thereto, more preferably 
O(CH2)CO-oligonucleotide where n is 1-7 and preferably 
1-3. 
In a further embodiment of the present invention, at least 
one of R-R is a site-directed molecule or is a couple to 
a site-directed molecule. In a more preferred embodiment, 
the site-directed molecule is an oligonucleotide or is a 
couple to an oligonucleotide and most preferably, the oli 
gonucleotide is a deoxyribonucleotide and the phosphate 
ester to be cleaved is RNA. The oligonucleotide has comple 
mentary binding affinity for the RNA in a region proximal to 
the phosphate ester bond being hydrolyzed. The oligonucle 
otide may have complementary binding affinity for viral 
RNA. in particular, retroviral RNA, or for bacterial riboso 
mal RNA, thereby cleaving the viral RNA or bacterial RNA 
and killing the organism. The oligonucleotide may have 
complementary binding affinity for mRNA, thereby cleaving 
the mRNA and modulating or interfering with the activity of 
the RNA such as, for example, the translation of mRNA into 
a protein. When the phosphate esteris RNA, the metal cation 
is preferably yttrium or a lanthanide metal cation, more 
preferably, Y(III), Tb(III). Eu(III) or Dy(III). 
The oligonucleotide may be a deoxyribonucleotide and 
have complementary binding affinity for oncogenes. The 
site-directed molecule may have binding specificity for 
localization to a treatment site and the biological receptor 
may be localized to a treatment site. 
Water-soluble texaphyrins are often preferred for the 
applications described herein, particularly when in vivo 
administration and treatment are contemplated. "Water 
soluble” means soluble in aqueous fluids to about 1 mM or 
better. Such characteristics allow these texaphyrins to be 
useful in a biological environment. Improved water solubil 
ity can be achieved by, for example, substituents chosen 
from saccharides or hydroxylated substituents. 
Although a survey of lanthanide (III) texaphyrin com 
plexes indicates that all of the metal complexes examined 
are capable of hydrolytically cleaving RNA, complexes of 
terbium(III) and dysprosium(III) cleave RNA faster than 
other lanthanides of those tested thus far. Additionally, while 
it is believed that complexes of lanthanoid metals will also 
cleave RNA hydrolytically, it has been found that yttrium 
(III) complexes perform very well. 
While all of the above-described texaphyrins are presently 
preferred compounds, the invention is not limited thereto 
and any metallotexaphyrin complex having catalytic activity 
for phosphate ester hydrolysis may be useful in the practice 
of the invention. 
An individual skilled in the art of organic synthesis in 
light of the present disclosure is able to prepare a large 
variety of texaphyrins and metallotexaphyrin complexes, 
which are expected to hydrolytically cleave phosphate 
esters, an important biological species. 
Texaphyrin compounds and methods for making are 
described in U.S. Pat. Nos. 4935.498, 5.162,509, 5.252,720, 
5.272,142 and 5.256399, each of which is incorporated by 
reference herein. 
Generally, the introduction of hydroxy substituents on the 










accomplished by their attachment to phenylenediamine in 
the 4 and 5 positions of the phenyl subunit of the molecule 
or they may be added in a synthetic step following the 
condensation step that forms the macrocycle metal complex 
as described in the above-named patents. The introduction of 
hydroxy substituents on the T (tripyrrole or tripyrrane) 
portion of the molecule is accomplished by appropriate 
functionalization of the alkyl substituents in the 3 and/or 4 
positions of the pyrrole rings at a synthetic step prior to 
condensation with the substituted phenylenediamine. Stan 
dard deprotection methodology such as ester hydrolysis may 
be used to unmask free hydroxyl substituents. Alternatively, 
they may be prepared as the result of ester reduction. These 
derivatives exhibit significant solubility in aqueous media. 
up to 1 mM or better, yet they retain affinity for lipid-rich 
regions which allows them to be useful in biological envi 
ronmentS. 
One skilled in the art of organic synthesis in light of the 
present disclosure and the disclosures in the patents, appli 
cations and publications incorporated by reference herein 
could extend and refine the basic synthetic chemistry to 
produce texaphyrins having various substituents. For 
example, a doubly carboxylated texaphyrin in which the 
carboxyl groups are linked to the texaphyrin core via aryl 
ethers or functionalized alkyl substituents could be con 
verted to various esterified products wherein the ester link 
ages serve to append further hydroxyl-containing substitu 
ents. Polyhydroxylated texaphyrin derivatives may be 
synthesized via the use of secondary amide linkages. Sac 
charide moieties may be appended via amide bonds. Poly 
hydroxylated texaphyrin derivatives containing branched 
polyhydroxyl (polyol) subunits may be appended to the 
texaphyrin core via aryl ethers or ester linkages. 
Treatment of carboxylated texaphyrins with thionyl chlo 
ride or p-nitrophenol acetate would generate activated acyl 
species suitable for attachment to monoclonal antibodies or 
other biomolecules of interest. Standard in situ coupling 
methods (e.g., 1.1'-carbonyldiimidazole) could be used to 
effect the conjugation. 
The selectivity of the texaphyrins may be enhanced by 
covalently linking oligonucleotides onto the periphery of the 
macrocycle. Amides, ethers and thioethers are representative 
of linkages which may be used for this purpose. Oligonucle 
otides functionalized with amines at the 5'-end, the 3'-end or 
internally at sugar or base residues may be modified post 
synthetically with an activated carboxylic ester derivative of 
the texaphyrin complex. Alternatively, oligonucleotide ana 
logs containing one or more thiophosphate or thiol groups 
may be selectively alkylated at the sulfur atom(s) with an 
alkyl halide derivative of the texaphyrin complex. The 
resultant oligonucleotide-complex conjugates may be 
designed so as to provide optimal catalytic interaction 
between a target nucleic acid and the bound texaphyrin. The 
oligonucleotide may be large enough to bind probably at 
least about 9-12 nucleotides of complementary nucleic acid. 
Specific methods for preparing texaphyrin-oligonucleotide 
conjugates are disclosed in WO 94/29316, incorporated 
herein by reference. 
The use of metallotexaphyrin complexes to hydrolyze 
phosphate esters, such as RNA, in vivo as a treatment 
procedure relies on the effective localization of the complex 
to the site of desired cleavage. A site of desired cleavage may 
be a position novel to undesired organisms in terms of health 
care. A site of desired cleavage may be an RNA encoding a 
product deleterious to the host or may be a normal RNA that 
is deleterious in some way. Treating native RNA with the 
metallotexaphyrin complexes in a site-specific manner 
results in the metallotexaphyrin complex binding to a 
complementary RNA sequence via an appended oligonucle 
otide. The metallotexaphyrin complex then cleaves the RNA 
proximal to this specific site. 
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Texaphyrin metal complex-oligonucleotide conjugates 
(metallotexaphyrin-oligonucleotide conjugates) may be 
developed into antisense reagents useful in the present 
invention. This antisense strategy provides a clear and 
rational method for new drug design because there is one 
requirement, namely that the antisense probe hybridize to its 
target molecule. The hybridization requirement is very well 
understood via complementary Watson-Crick or Hoogsteen 
base pairing. Unlike the present methods in the art which 
require screening of thousands of compounds and X-ray 
crystal structure analysis, the information needed for anti 
sense technology is the sequence of the target. Treating 
native RNA with a metallotexaphyrin-oligonucleotide con 
jugate results in the conjugate binding to a complementary 
RNA sequence via the appended oligonucleotide. The met 
allotexaphyrin complex then hydrolyzes the RNA proximal 
to this specific binding site. The metallotexaphyrin complex 
enhances the therapeutic activity of the antisense 
oligonucleotide, not only by facilitating cellular uptake of 
the oligonucleotide but also by hydrolyzing the target RNA 
within the cell independent of RNase H. Additionally, 
attachment to the texaphyrin complex causes the oligonucle 
otide antisense agent to take on some of the pharmacody 
namic and biodistribution properties of the texaphyrin such 
as selective localization in tumors. 
The metallotexaphyrin-oligonucleotide ribozyme analog 
approach to antisense therapy can be applied to virtually any 
oligonucleotide backbone and may overcome many of the 





ing oligonucleotide uptake in cells and enhancing the activ 
ity of the oligonucleotide, metallotexaphyrins should allow 
for the development of more efficacious antisense therapeu 
tic products. The ribozyme analog sequence need only be of 
sufficient length to specifically recognize its RNA target, 
typically 12-15 residues. This is much shorter than actual 
ribozymes, which are considerably longer in order to contain 
the structural features necessary for catalytic activity. By 
selecting appropriate oligonucleotide backbones that recog 
nize specific RNA sequences. the metallotexaphyrin 
ribozyme analog approach may be used in therapeutic 
approaches to cancer, viral diseases such as HIV and 
hepatitis, and other disorders such as autoimmune diseases 
and restenosis. Other applications of this technology include 
in vitro site-specific RNA cleavage for use in diagnostics or 
as reagents, such as custom-made restriction enzyme ana 
logs. 
The texaphyrin complex-oligonucleotide conjugates may 
be useful for inhibiting the expression of a gene in an animal 
or in a particular tissue of an animal. They are also useful in 
a method for targeted intracellular RNA hydrolysis, and 
especially intracellular messenger RNA hydrolysis. 
The present method of hydrolysis would have immediate 
applications for anti-viral and anti-bacterial therapy as well 
as for cancers (an oligonucleotide complementary to an 
oncogene, for example) and inflammatory responses that are 
caused by the overexpression of certain proteins. 
Exemplary texaphyrins useful in the present invention are 
listed in Tables A-C, see below. 
TABLE A 
Representative Substituents for Texaphyrin Macrocycles Al-A50 of the Present Invention. 
Substituents for RI-R are provided in TABLE A and for RI-Ra in TABLE B. 
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Representative Substituents for 
Texaphyrin Macrocycles of the Present invention 
(Rs. Ra, and Ro-R2 are H) 
TXP R R2 R R R Rs 
COOH 
B24 CHCH- " 4. 
CON 
oligo 
B25 CH(CHOH CHCH CHCH, OCHCOOH O(CHCHO)CH 
CH-N- 
imidazole 
B26 p O(CH2)CO-histamine H 
B27 s O(CH2)CO-arginine p 
methyl ester 
B28 J O(CHCO-amino 
acid, n = 1-7 
B29 O(CH)CON-catalytic 
group, n = 1-7 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. Although any methods and materials 
similar or equivalent to those described herein can be used 
in the practice or testing of the present invention, the 
preferred methods and materials are now described. Unless 
mentioned otherwise, the techniques employed herein are 
standard methodologies well known to one of ordinary skill 
in the art. 
EXAMPLE 1. 
Hydrolysis of Monoesters by Lanthanide(III) T2B2 
Texaphyrin 
The present example provides the utility of the present 
invention in the use of metallotexaphyrin complexes for the 
hydrolysis of monoesters, in particular, the hydrolysis of 
UpU, cuMP. 3'-UMP and 2'-UMP. 
Cytosine, uridine, uridine-2'- and -3'-monophosphate 
disodium salt (2'-UMP and 3'-UMP), uridine-2',3'- 
cyclicmonophosphate sodium salt (cUMP), and uridylyl 
(3'-5') uridine ammonium salt (UpU) were purchased from 
Sigma (St. Louis. Mo.) and used without further purification. 
The lanthanide texaphyrins were prepared as described in 
detail in WO 94/29316, the entire disclosure of which is 
incorporated herein by reference. All solutions, unless oth 
erwise stated, were prepared from a stock solution of 5.0 
mM N-(2-hydroxyethyl)piperazine-N-ethanesulfonic acid 
(HEPES), in Milli-Q purified water, adjusted to pH 7.0. 
Solutions were stored and reactions conducted in RNAse 
free plastic vials further sterilized by heating at 120° C. for 
20 minutes in an autoclave. Gloves were worn at all times 
during solution preparation and reaction sampling. All 
kinetic runs were thermostatted at 37° C. in a water bath. 
High-performance liquid chromatography (HPLC) was 
performed on a Waters 501 equipped with a Waters model 
440 absorbance detector, monitoring at 254 nm. A YMC, 
Inc., USA ODS-AQ column (150 mmx4.6 mm I.D.) was 
used. Satisfactory separation was achieved with an isocratic 
gradient (10 mM NaH2PO, adjusted to pH 5.6 with 1% 
methanol) with a flow rate of 1.0 ml/min. A Beckman DU-7 
spectrometer was used to confirm the concentrations of 
EuB2T2 txp. 
Eu (NO). In the control experiment, the reaction solu 








25 L of Eu(NO) (3.5 pm), and 100 pull of cytosine (0.423 
mM), as internal standard, in 375 L of 5.0 mM HEPES 
solution. The reactions were carried out as for EuB2T2 txp. 
The pseudo-zero order rate constant for the control reaction 
was determined to be k=(2.20.8)x10 mM/hr. 
EuB2T2 txp. Europium(III) B2T2 texaphyrin ("EuB2T2 
txp", cpd. 8) was prepared and described in WO94/29316. 
OH 
OH 
R = Rs = OCHCHCH-OH ("EuB2T2 tip") 
R = H, R= OCHCO2H 
8c R = H, R= OCH2CO-DNA 
In a typical kinetics experiment, the reaction solutions 
were prepared by diluting 100 L of UpU (2.94 mM), 50 L 
of EuB2T2 txp (7.8 mM), and 100 L of cytosine (0.423 
mM), as internal standard, in 350 L of 5.0 mM HEPES 
solution. The rate of UpU hydrolysis was monitored by 
removing 15 ul aliquots which were frozen until HPLC 
analysis was possible. All samples were microfiltered (0.2 
Im) prior to injection on the HPLC. All runs were performed 




taneous control containing no metal complex was negligible. 
The pseudo-zero order rate constant for the reaction was 
determined to be k=(9.1+1.6)x10 mM/hr at 37° C. pH 7.0. 
The pseudo-zero order rate constant for the hydrolytic 
cleavage of a ribodinucleotide by the nitrate salt of the 
water-soluble EuB2T2 texaphyrin was examined. Investiga 
tions indicated that a 0.15 mM aqueous solution of Eu(B2T2 
txp)" hydrolytically cleaved uridylyl (3'-45") uridine, 
UpU, (0.49 mM) with a pseudo-Zero zero order rate of 
(9.1+1.6)x10 mM/hr at 37° C. pH 7.0. In the absence of 
the metal complex no evidence of RNA cleavage was 
observed by HPLC. The reaction was followed by HPLC, 
monitoring the formation of uridine. Uridine-2'- 
monophosphate, uridine-3'-monophosphate, and uridine-2', 
3'-cyclicmonophosphate (cuMP) were also observed by 
HPLC; this indicates a hydrolytic rather than an oxidative 
mechanism for the cleavage reaction. Uridine-2',3'- 
cyclicmonophosphate reached a steady state concentration, 
implying that the texaphyrin complex hydrolyzed cuMP as 
well. Under identical conditions, a 0.15 mM aqueous solu 
tion of Eu(NO) has a pseudo-Zero order rate constant of 
(2.2+0.35)x10 mM/hr. Therefore, small traces of free 
metal ions cannot account for the hydrolysis observed in the 
presence of the metallotexaphyrin complex. Under these 
conditions, the Eu(III) complex of HAM displayed a 
pseudo-zero order rate constant of 4.1x10 mM/hr. Thus, 
the texaphyrin complex is found to be more effective than 
the HAM system. 
A survey of other lanthanide (III) complexes of B2T2 






of RNA hydrolysis. Results are summarized in Table 2. 
TABLE 2 
Rate Constants (Pseudo-Zero Order) for the Hydrolysis 
of UPU by Lanthanide(II) B2T2 Texaphyrin Complexes 
LANTHANDE CATION k mM/h 
La(TTI) 1.16 x O' 
Nd(III) 4.69 x O' 
Sm(III) 6.3 x iO 
Eu(III) 499 x 10 
Gd(III) 144 x 10 
Dy(III) 60 x O. 
TmII) 4.16 x 10' 
Lu(III) 1.9 x 10 
The concentrations of the Lanthanide(III)B2T2 txp(NO) 
were all approximately 0.25 mM. 
Further evidence supporting the catalytic effect of the 
metallotexaphyrin complex was obtained by monitoring the 
formation of uridine produced from the Eu(T2B2Txp)" 
catalyzed de composition of uridine-2',3'- 
cyclicmonophosphate (cuMP). The decomposition of 
cUMP (0.10 mM) catalyzed by Eu(T2B2Txp)" (0.15 mM), 
when incubated at 37° C. and pH=7.0 (5 mM HEPES 
buffer), had a pseudo-zero order rate of 6.94x10 mMh' 
for the production of uridine. Examination of the reaction 
products by HPLC indicated that initially cUMP is isomer 
ized to uridine-3'-monophosphate (3-UMP) and uridine-2'- 
monophosphate (2'-UMP), which are subsequently hydro 
lytically cleaved to produce uridine. as illustrated below. 
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Generalized Hydrolysis of RNA Using a 
Metallotexaphyrin Complex 
This example describes the degradation of a homogenous 
population of RNA molecules with EuB2T2 texaphyrin. 
P'-labelled RNA transcripts from an isolated clone was the 
homogenous RNA substrate. The transcripts and their deg 
radation products were visualized by polyacrylamide gel 
electrophoresis and autoradiography. 
pGEM6)-3Z vector and Riboprobe® RNA transcript sys 
tems were obtained from Promega Corporation, Madison, 
Wis. A 4.3 kb fragment of the mouse 1b Multi Drug 
Resistant gene (MDR) was cloned into the EcoRI site of the 
pGEM 37 vector and its orientation determined (see FIG. 1). 
The plasmid was used in transcription reactions and, when 
digested with BamHI. T7 RNA polymerase makes a tran 
script from this template that is approximately 2000 bases 
long. The transcription reaction consisted of 100 ng of 
BamHI digested pCEM 3Z4.3 MDR#3, 20 L of 5x tran 
scription buffer, triphosphate nucleotides (ACG) at 500 
uM, UTP at 100M, 50 Cof-Pol-UTP (3000 Ci/mmol). 
10 mmol DTT, 120 units of RNasin and 70-100 units T7 
RNA polymerase. This reaction was brought up to a total 
volume of 100 L with DEPC treated double distilled water. 
The reaction was allowed to incubate at 37° C. for 1.5 hours. 
The entire reaction volume was then run over a G-50 
Sephadex column (Nick column. Pharmacia) pre 
equilibrated with 20 mM Tris pH 7.0, 2 mM EDTA, 0.1% 
SDS. The transcript was eluted from the column in the 
second 400 L volume applied to the column. Any unincor 
porated nucleotide was left on the column. 
Ten-Laliquots of the transcript were put into separate 
tubes, and stock solutions of EuB2T2txp. EDTA or Eu(III) 
acetate (EuOAc) were added so that the final volume was 20 
L. The tubes were allowed to incubate for 2 hr at 37° C. 
Thirty L of dye mix (formamide, 0.2% bromphenol blue) 
was added to each tube. The tubes were mixed and heated at 
60° C., 5 min, then the entire content of the reaction was 
loaded onto a 5% 8M urea polyacrylamide gel and electro 
phoresis was performed. The gel was set up as follows: Lane 
1, control, no EuB2T2 txp; lane 2, control with EDTA; lanes 
3-7, EuB2T2 txp. 100M, 50 M, 25M, 10M and 5M; 
lanes 8–10, EuB2T2 txp, 100M and EDTA at 500M,300 
M and 100 M; lane 11, M.W. std; lane 12, control, no 
EuB2T2 txp; lane 13, EuB2T2 txp, 100 M and EDTA, 10 
M. 
The results of the digests of the 2000 base long transcripts 
with EuB2T2 txp were as follows: There was one band in the 
control and control with EDTA lanes 1, 2 and 12. This band 
was absent in the lane with 100MEuB2T2 txp, lane 3. An 
increase in lower molecular weight material. i.e. degradation 
products, was seen as smearing throughout lane 3. The 
transcript remained intact at the lower EuB2T2 txp 
concentrations, lanes 4-7. The transcript was degraded with 
100MEuB2T2 txp in the presence of 500, 300, 100 and 10 
uM amounts of EDTA, lanes 8-10 and 13. This experiment 
eliminates the possibility that free metal in the EuB2T2 txp 
solution was causing the degradation. Lane 11 contained 
molecular weight standards of 1418 and 679 bases. The 100, 
50, 25, 10 and 5M concentrations of free europium metal 
salt (EuOAc) did not digest the transcript, lanes 3–7. These 
results were not affected by the presence of EDTA, 
A digestion of total RNA (primarily 28s and 18s riboso 
mal RNA from K562 cells) with EuOAc, EuT2B2 txp and 













RNA. The digestions were performed in 50% DMSO and 
HO, and the gel was electrophoresed using a 10 M 
phosphate buffer, pH 6.8. It is likely that EuOAc digests the 
homogeneous transcript also but at higher EuOAc concen 
trations than those used in the present example. 
Clearly, EuB2T2 txp is able to hydrolyze RNA substrates. 
Since the texaphyrins have such versatility for 
functionalization, this result has significant implications for 
the construction of site-specific cleaving reagents for nucleic 
acids and other molecules as discussed further in the foll 
lowing examples. 
EXAMPLE 3 
Site-Specific Hydrolysis of RNA by Europium(III)- 
Texaphyrin Conjugated to a Synthetic 
Oligodeoxyribonucleotide 
The present example provides antisense agents using a 
metallotexaphyrin complex-oligonucleotide conjugate that 
effects the hydrolysis of its RNA complement. Such anti 
sense agents should therefore be able to act in vivo without 
the participation of endogenous nucleases. A EuTx-DNA 
oligonucleotide conjugate was synthesized based on the 
functionalized texaphyrin 8. This "ribozyme analogue" 
(cf. 8) provides an example of oligodeoxynucleotide 
directed, metal-catalyzed hydrolysis of a complementary 
RNA oligomer. 
Two 20-mer oligonucleotides were machine-synthesized 
to contain alkylamine groups at either the 5-position of an 
internal thymine residue or the 5'-end terminal phosphate. 
Oligodeoxynucleotide-amines modified on the 5-position of 
thymine were purchased from Oligo's Etc. (Wilsonville, 
Oreg.); oligodeoxynucleotide-amines modified on the 5' end 
were purchased from Keystone Laboratories, Inc. (Menlo 
Park, Calif.). Oligonucleotides were HPLC purified and 
precipitated using LiCl prior to use. Reaction of the car 
boxylic acid functionalized europium(III) texaphyrin com 
plex 8 with carbodiimide and N-hydroxysuccinimide pro 
duced the corresponding activated ester, which was added 
directly to a solution of the chosen oligodeoxynucleotide 
amine. The resulting DNA-EuTx conjugates (FIG. 2, 9) 
were purified by electrophoresis. 
A synthetic RNA 30-mer (10 FIG. 3) was obtained as 
substrate (Keystone Labs, Inc., Menlo Park, Calif.), with a 
sequence selected from a unique site within the gene tran 
script for multiple drug resistance. The sequence is comple 
mentary at 1562 bases post-transcriptional start site in 
mouse multidrug resistance protein mRNA. The 3'-P- 
labelled substrate was incubated with an excess of oligode 
oxynucleotide conjugate at 37° C. for 18-24 hr in a buffered 
salt solution, precipitated with ethanol, and assayed on a 
20% denaturing polyacrylamide gel. Ca. 1.5x10 cpm of 
substrate was incubated in a total volume of 20 L of buffer 
containing 50 mM HEPES. pH 7.5, 100 mM NaCl, 25 M 
EDTA and 5 g/mL calf thymus DNA. Lane 1, no DNA, 
control; lane 2, control with unmodified oligodeoxynucle 
otide 9 lane 3, 2.5 M 8; lane 4, 25M 8, lanes 5-7, 9 
and, respectively, 250 nM, 2.5M, and 25 M of 8; lane 8, 
9; lane 9,9; lane 10, 9; lanes 11-14, 9 at 2.5 nM, 25 
nM, 250 nM, and 2.5M, respectively. All other oligonucle 
otides were at 2.5 M final concentration. Nucleotide 
sequence analysis was determined by partial digestion with 
base-specific ribonucleases: T1C); U2 (ADG); Phy M 
(U+A); B. cereus (U+C); HCO (alkaline hydrolysis); PNK 
(polynucleotide kinase-treated HCO lane). 
As illustrated schematically in FIG. 3, ca. 30% cleavage 
occurred near the expected location of the Eu-texaphyrin 
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complex upon hybridization with conjugate 10O. Cleavage 
yield was measured by densitometry and calculated as ratio 
of cleavage band to intact material. The corresponding 
cleavage bands were not observed when this same substrate 
was incubated with oligonucleotides that were non 
complementary in sequence. unmodified, or were modified 
internally with the complex. Control reactions indicated that 
ambient light, calf thymus DNA or type of buffer (Tris 
acetate or HEPES, EDTA, pH 6.0-8.0) had no apparent 
effect on cleavage efficiency. EDTA inhibits cleavage by free 
lanthanide(III) cations as observed in Morrow et al. (1992). 
Hydrolysis of 5'-end labelled RNA 30-mer 10 by con 
jugate 10 (a 5' EUTx conjugate having an oligonucleotide 
complementary to substrate 10) was demonstrated, follow 
ing the above procedures. Test 1: 5'-End labelled RNA 
30-mer 10 substrate was incubated with 2.5 M EuTx 
DNA conjugate 10 (9) for 24 hr at 37° C. (lanes 3-6) or 
25°C. (lanes 7-14) in buffers containing 100 mM NaCl. 
Key: lane 1. non-incubated RNA control; lane 2, ribonu 
clease T1 (G) reaction; lanes 3, 8.50 mM HEPES, pH 7.5. 
25 M EDTA; lanes 4.9, 50 mM HEPES, pH 7.0, 25 M 
EDTA; lane 5, 10:50 mM TrisAcetate pH 7.5.25M EDTA; 
lanes 6.11.14, 50 mM Tris Acetate pH 7.0, 25 M EDTA; 
lane 7, 50 mM HEPES. pH 7.5; lanes 12, 13, 50 mM 
Tris Acetate, pH 7.0; lane 13.5M Fe(II), 4 mM DTT, 5 M 
non-modified oligo 9; lane 14, no conjugate control. Test 2: 
5'-End labelled RNA30-mer 10 substrate was incubated for 
25 hr at 37° C. in 50 m HEPES (or Tris Acetate, lane 6) 
buffer containing 100mMNaCl, 25uM EDTA, and 5ug/mL 
calf thymus DNA. Key: lane 1. no DNA control; lane 2. 
non-modified oligodeoxynucleotide 9 (2.5 M); lane 3,9. 
(2.5 FM); lane 4.9 (2.5 M); lanes 5-9, 9 (') (250 nM). 
Comparison of lanes 3-6 with lanes 7-14 of the Test 1 gel 
indicated that hydrolysis occurred more readily at 37° C. 
than at 25°C. Lane 3 of the Test 2 gel demonstrated that a 
noncomplementary oligo 9 did not effect hydrolysis of 10 
and lane 4 of the Test 2 gel demonstrated that a conjugate 
having a complementary oligo and EuTx bound to an 
internal T residue did not effect hydrolysis of the RNA 
substrate. Lanes 5-9 of the Test 2 gel demonstrated hydroly 
sis of the RNA substrate by 10, 
The cleavage fragments co-migrated with bands in 
sequencing lanes produced by incubation of substrate under 
alkaline conditions or subjected to partial digestion with a 
series of base-specific ribonucleases (For an example of a 
similar end-product analysis, see Dange et al., 1990). This 
observation is consistent with a hydrolytic mechanism, 
presumably involving the EuTx acting as a Lewis acid that 
facilitates an intramolecular attack of the 2'-hydroxyl group 
to effect cleavage. There were bands indicating site-specific 
cleavage of the ribonucleotide target sequence in the 
absence of any added cleavage reagents. Although the 
source of this background cleavage is unknown, it is 
believed to be the direct result of a higher order structure 
(ie... a hairpin) of the oligoribonucleotide, since hybridiza 
tion with any complementary oligonucleotide dramatically 
inhibited the cleavage. This type of structure-dependent 
cleavage behavior has been seen previously with oligoribo 
nucleotides (Dange et al., 1990, Kazabov et al., 1992). 
Maximal cleavage activity of the EuTx-oligonucleotide 
was observed down to 25 nM conjugate. Decreased cleavage 
below this level may be due to a decrease in hybridized 
material (as judged by increased background cleavage of the 
target RNA present at a concentration of about 1 nM). By 
means of comparison, the free europium complex non 
specifically hydrolyzed the RNA substrate at 25 M. In the 










derivatized complementary DNA oligomer, cleavage 
occurred predominantly in the single-stranded region, 
although still at lower efficiency than the EuTx-DNA con 
jugate at 2.5 nM. Thus, attachment of the EuTx to the DNA 
probe increases its effective concentration ca. 10,000-fold. A 
target RNA without the secondary structure observed here 
would likely allow for cleavage at lower DNA-EuTx con 
centrations. These data indicate the utility of such conjugates 
in antisense applications. 
As demonstrated in the present example, the selectivity of 
the texaphyrin complexes is enhanced by covalently linking 
oligonucleotides onto the periphery of the macrocycle. Since 
the metal complexes do cleave RNA over DNA 
preferentially, the DNA appendages would remain intact 
during the hydrolysis experiments. The DNA arm will 
recognize and bind to an appropriate RNA segment, effec 
tively increasing the metal concentration at these loci rela 
tive to the overall metal concentration in solution. Phosphate 
ester hydrolysis will therefore be significantly increased at 
specific locations along the RNA backbone. In one 
embodiment, primers (known or deduced) for PCR could be 
coupled to a hydrolytic divalent or trivalent texaphyrin 
complex to induce hydrolysis of proximal RNA. 
Enhancement of RNA hydrolysis by the metallotexaphy 
rin complex-conjugate may be accomplished by designing 
the deoxyribonucleotide to bind to the RNA target so as to 
produce a single-stranded loop which may have increased 
susceptibility to hydrolysis. The loop may contain one or 
more nucleotides. In this case, the oligodeoxyribonucleotide 
acts as a catalytic group by using the energy of its binding 
to the RNA target to increase the ground state energy of the 
targeted phosphate diester. Examples are illustrated in FIGS. 
4A and 4.B. FIG. 4A shows a DNA twelve-mer lacking a 
nucleotide to base pair with the looped out “U” and conju 
gated at its 5' end to a Dy(III) texaphyrin complex. Binding 
to the RNA substrate causes a one-base loop structure that is 
a site of enhanced susceptibility to hydrolysis by the Dy(III) 
Txp complex. FIG. 4B shows a DNA ten-mer lacking the 
same nucleotide, conjugated to a Dy(IITxpat its 3' end and 
to a second Dy(III)Txp at its 5' end, binding to the RNA 
substrate so as to cause the same one-base loop structure. 
The loop is a site of enhanced susceptibility to hydrolysis, 
this time by the two Dy(III)Txp complexes which converge 
on the loop structure upon binding. In this example, one 
Dy(DDTxp may act as a general acid and the second may act 
as a general base via a Dy(III)Txp-bound hydroxyl group for 
activating the RNA towards hydrolysis. 
EXAMPLE 4 
Site-Specific Hydrolysis of RNA by Dysprosium 
(III)-Texaphyrin and Europium(III)-Texaphyrin 
Conjugated to Synthetic Oligodeoxyribonucleotides 
of Varying Lengths 
Following the procedures of Example 3, 
oligodeoxyribonucleotide-amines of varying nucleotide 
lengths and modified at the 5' end (obtained from Keystone 
Labs, Menlo Park, Calif.) were reacted with carboxylic acid 
functionalized dysprosium(III)-texaphyrin complex 8 to 
give DyTx-oligo conjugates 9-9 (FIG. 2) Corresponding 
EuTx-oligo conjugates were also prepared, 
Each of the above-described conjugates was then incu 
bated with the 3'-labeled synthetic RNA30-mer 10, follow 
ing the procedures of Example 3. Labelled substrate ((5'-end 
labelled RNA 30-mer 10 (lanes 1-9) or 36-mer 10 (lanes 
12-18) was incubated with or without 250 nM conjugate 
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for 24h at 37° C. in buffer containing 100 mMNaCl. 50 mM 
HEPES pH 7.5, 25 M EDTA. They were then placed on a 
20% denaturing polyacrylamide gel. Key: lanes 1, 12, no 
conjugate, control; lanes 2, 6, 13, 9; lanes 3, 7, 14.9; lanes 
4, 8, 15, 9; lanes 5, 9, 16, 9; lanes 10, 17. HCO 
sequencing; lanes 11, 18, base-specific ribonuclease U2 (A) 
sequencing. Reactions corresponding to lanes 1-5 were 
conducted under inert (argon) atmosphere, while reactions 
corresponding to lanes 12-16 were conducted under oxygen. 
All of the conjugates having complementary DNA and a 
texaphyrin complex at either end of the oligo hydrolytically 
cleaved the RNA, although the RNA was hydrolyzed by the 
Dy conjugates at about twice the rate (producing ca. 60% 
cleavage of the RNA) as by the Eu conjugates. At the 250 
nM concentration of DNA used, the 12-mer conjugate was 
found to be as effective as the 20-mer conjugate, the 9-mer 
conjugate was less effective and only a small amount of 
cleavage was observed with the EuTx-9 mer conjugate, 
Increased background cleavage of the RNA substrate in the 
presence of the 9-mer conjugate indicates a lower degree of 
binding by the shorter oligonucleotide. 
These data indicate that oligonucleotides having as few as 
12 bases provide the specificity needed for accurate and full 
hydrolytic activity. This aspect is important for drug design, 
since the ability of an oligonucleotide analog to traverse a 
cellular membrane is generally found to be inversely pro 
portional to its length. 
EXAMPLE 5 
Site-Specific Hydrolysis of a 36-Mer RNA by 
Dysprosium(III)-Texaphyrin Conjugated to a 
Synthetic Oligodeoxyribonucleotide 
A3'-labelled synthetic RNA36-mer 10 (Promega Corp., 
Madison, Wis.) (FIG. 3) was incubated with an excess of the 
DyTx-oligo conjugate 10(9), following the procedures of 
Example 3, and the hydrolysis observed. As illustrated 
schematically in FIG. 3, the DyTx-oligo conjugate hydro 
lyzed the RNA at positions indicated by the arrows. This 
additional result supports the breadth of utility for the 
texaphyrin-oligonucleotide conjugates in the hydrolysis of 
ester bonds. 
EXAMPLE 6 
Synthesis of Texaphyrin-Oligonucleotide 
Conjugates Having a Texaphyrin Attached to the 3' 
end of the Oligonucleotide 
Two oligodeoxyribonucleotides of 12 bases each were 
synthesized to contain alkylamine groups at the 3' terminal 
phosphate (Keystone Labs, Menlo Park, Calif.). These oli 
gomers were reacted with carboxylic acid functionalized 
Eu(II)-texaphyrin complex. 8 or a Lu(III)texaphyrin func 
tionalized complex corresponding to 8 following the pro 
cedures of Example 3. to give conjugates 9, 9 and 9 (FIG. 
2). 
These 3'-conjugates may be of particular importance in 
certain embodiments of the present invention, since attach 
ment of large groups (such as the present texaphyrin 
complexes) to the 3' end of oligonucleotides renders the 
oligonucleotide resistant to cellular "nucleases. 
In a similar manner, an embodiment of the present inven 
tion is the addition of particular ligands to the 3' end of an 
oligonucleotide having its 5' end conjugated to a texaphyrin. 
The function of the 3' ligand is to aid in the uptake of the 
conjugate into the cell. Such ligands are known in the art and 













A further embodiment of the present invention in the 
hydrolysis of RNA using metallotexaphyrin complex 
oligonucleotide conjugates is the use of a set of two 
conjugates, one having the metallotexaphyrin complex con 
jugated to the 5' end of an oligomer and the other having a 
metallotexaphyrin complex conjugated to the 3' end of an 
oligomer and the oligomers are complementary to the same 
RNA substrate, one just upstream from the other, so as to 
position both metallotexaphyrin complexes in proximity to 
the targeted hydrolysis site as depicted in FIG. 5. The 
distance separating the two catalytic groups may be varied 
by preparing a nested set of oligomer-5'-conjugates of 
varying lengths and comparing the hydrolysis efficiencies 
that result upon the simultaneous binding of the two con 
jugates to the RNA template. 
EXAMPLE 7 
Synthesis of an Eu(III) Texaphyrin-Oligonucleotide 
Dual Conjugate 
An oligodeoxyribonucleotide having 12 bases was syn 
thesized to contain alkylamine groups at both the 3' and the 
5' ends (Keystone Labs, Menlo Park, Calif.). This oligomer 
was reacted with an excess of the carboxylic acid function 
alized Eu(II)-texaphyrin complex. 8, following the proce 
dures of Example 3, to give the dual conjugate 9, (FIG. 2) 
which has an Eu(III)Tx metal complex at both the 3'- and the 
5'-ends of the 12-mer. 
The use of two texaphyrin-metal complexes conjugated to 
the same oligonucleotide, one at each end, should effect the 
hydrolysis of RNA with increased efficiency due to the 
concerted activity of the metal complexes. In this 
embodiment, it is preferred that both of the texaphyrin 
complexes contain the same metal. preferably yttrium or a 
lanthanide metal cation and more preferably Y(III), Eu(III) 
or Dy(III). One of the metallotexaphyrin complexes may act 
as an acid and the second may act as a base in order to 
further activate the RNA towards hydrolysis. 
Further, a dual conjugate provides versatility in the func 
tions that may be accomplished by this one molecule. For 
example, the oligonucleotide provides binding specificity. 
one metallotexaphyrin complex may provide for imaging 
(having Gd(III) as the metal ion, for example) while the 
other provides for phosphate ester hydrolysis. Such a dual 
conjugate allows for two functions, imaging and hydrolysis, 
to be effected by one molecule. 
The use of metallotexaphyrin complexes to cleave RNA 
in vivo as a treatment procedure relies on the effective 
localization of the complex to the site of desired cleavage. 
A site of desired cleavage may be a position novel to 
undesired organisms in terms of health care. A site of desired 
cleavage may be a messenger RNA encoding a product 
deleterious to the host or may be a normal RNA that is 
deleterious in some way. 
EXAMPLE 8 
Sequence-Specific Inhibition of Cell Proliferation 
by Dy(II) Texaphyrin Conjugated to a 15-mer 
Phosphorothioate 
The present example provides for the enhancement of 
antiproliferative activity of a 15-mer phosphorothioate 
directed toward an oncogene target (c-myc) which is 
observed upon conjugation to Dy(IIT)Tx (cpd. 8 where the 
metal is Dy). In general terms, a human promyelocytic 
leukemia cell line (HL-60, purchased from ATCC, 
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Rockville, Md.), maintained under conditions of exponential 
growth, was incubated in the presence or absence of an 
oligonucleotide test species. At periodic intervals (after 4 
and 7 days) an aliquot of cells was removed from culture and 
the number of viable cells was quantitated using a calori 
metric assay based on mitochondrial processing of dye 
(MTT), following the procedures of Mosmann, T.J Immu 
nol. Methods, 65 (1983) 55-63. 
HL-60 cells were maintained in exponential growth by 
adding fresh media (RPMI-1640, 10% FCS, L-glutamine) 
every 3-5 days. Stock cells were diluted with media to 
40,000 cells/mL and incubated for 24 h, whereupon 0.9 mL 
of diluted cells were pipetted into each well on a 24-well 
culture plate. Additions of oligonucleotide test species 11. 
11 or 11 were made from 100LM solutions, and DEPC 
treated water was added to achieve a final volume of 1 mL 
within each well. 
5'-H-(CH-PSO-GAG GCT GCT GGTTTT-3' 11 
5'-DyTxHN-(CH-PSO-GAG GCT GCT GGTTTT3' 11 





agent 11 or the sequence-nonspecific conjugate 11. These 
observations are consistent with a model whereby conjuga 
tion to DyTx facilitates the ability of a phosphorothioate 
oligomer to interfere sequence-specifically with the expres 
sion of an oncogene product, thereby inducing the terminal 
differentiation of a cancerous cell line. The probable mecha 
nisms responsible for this enhancement of antisense activity 
include improved uptake of the texaphyrin-conjugate by the 
cells, better intracellular targeting of the agent, and/or site 
specific hydrolysis of the c-myc messenger RNA by the 
DyTx upon hybridization. 
The data of Examples 1 through 8 demonstrate that 
texaphyrin-metal complexes may be developed into RNA 
antisense reagents. The antisense approach is efficient in 
regulating the expression of proteins. Many copies of a 
particular polypeptide or protein are made from one mes 
senger RNA molecule; therefore, by moving up in the levels 
of cellular processes and knocking out the message (the 
SEQ. ID NO. 17 
SEQ. ID NO. 17 
SEQ. ID NO. 18 
Conjugate 11 was compared side-by-side with its non 
conjugated analogue 11 on each of three 24-well plates, at 
5. 2.5 and 1.25 uM concentrations, respectively. Conjugate 
11 was also compared side-by-side with the sequence 
nonspecific conjugate 11 on each of three 24-well plates, at 
5, 2.5 and 1.25 M concentrations, respectively. Each spe 
cies was tested in triplicate. The 24-well plates were incu 
bated at 37° C. under a 5% carbon dioxide atmosphere. 
The concentration of cells in each well was determined at 
four days and at seven days using an MTT assay. Prior to 
sampling, each well was mixed by aspiration with a sterile 
pipette tip (P1000). A 75 mLaliquot was removed from three 
wells using a multichannel pipettor and transferred to a 
96-well plate. Two aliquots were removed in this way, 
resulting in six wells overall on the 96-well plate for each 
test species. To each well, 25 pull of MTT dye (2 mg/mL in 
RPMI-1640, L-glutamine, without phenol red) was added, 
and the reactions were incubated for 2–4 h. at 37° C. Before 
reading the absorbance of each well on a microplate reader 
(Molecular Devices, Sunnyvale, Calif.). 200 L of a solution 
(0.04M HCl in isopropyl alcohol. 10 vol%. Tween-20) was 
added to dissolve the precipitated dye, and the wells were 
mixed by aspiration. Absorbance was read at 570 nm and 
650 nm, with the latter reading used for a background 
subtraction. A set of standards, prepared from untreated cells 
by serial dilution, was run on each microplate in order to 
construct a calibration curve. 
Data comparing conjugate 11 and non-conjugated ana 
logue 11 are presented in FIG. 6; data comparing conju 
gates 11 and 11 are presented in FIG.7. Data for each test 
species are plotted as decrease in cell density relative to a 
control of DEPC-treated water. 
In this example, the antiproliferative activity of a 15-mer 
phosphorothioate oligonucleotide conjugated with DyTx 
was compared with the activity of the non-derivatized 
analogue of the same sequence and, in an independent 
experiment, with the activity of a 15-mer phosphorothioate 
conjugate which is sequence-nonspecific for the targeted 
RNA. In all cases, the phosphorothioates displayed a sig 
nificant background level of sequence-nonspecific inhibition 
of cell growth. However, the antisense conjugate 11 shows 
a dose-dependent activity beyond this which is significantly 








mRNA). fewer attacking agents would be required because 
there would be fewer target sites. The production of protein 
by an organism could be efficiently and effectively modu 
lated. The antisense strategy provides a clear and rational 
method for new drug design because there is one 
requirement, that the antisense probe hybridize to its target 
molecule. The hybridization requirement is very well under 
stood via complementary Watson-Crick base pairing. Unlike 
the present methods in the art which require screening of 
thousands of compounds and X-ray crystal structure 
analysis, the information needed for antisense technology is 
the sequence of the target. Treating native RNA with these 
texaphyrin complex-oligonucleotide conjugates results in 
the texaphyrin conjugate binding to a complementary RNA 
sequence via an appended oligonucleotide. The texaphyrin 
complex then cleaves the RNA proximal to this specific site. 
Either one or two texaphyrin molecules may be attached to 
the DNA. creating the potential for gene splicing reagents. 
The texaphyrin oligo conjugate would have immediate 
applications for in vitro, ex vivo or in vivo anti-viral and 
anti-bacterial therapy as well as cancers (an oligonucleotide 
complementary to an oncogene, for example) and inflam 
matory responses that are caused by the overexpression of 
certain proteins. Antisense technology is discussed in U.S. 
Pat. Nos. 5,194,428, 5.110,802 and 5,216,141, all of which 
are incorporated by reference herein. 
EXAMPLE 9 
Texaphyrin-Sapphyrin Conjugates for Ester 
Cleavage and Transport Across Membranes 
A further means of gaining selectivity is to link covalently 
the texaphyrin complex to a sapphyrin (sap) molecule. 
Sapphyrins are disclosed in, e.g., Sessler et al., 1992; Furuta 
et al., 1991; Sessler et al., 1991; U.S. Pat. No. 5,159,065; 
U.S. Pat. No. 5,120,411; U.S. Pat. No. 5,041,078, all incor 
porated by reference herein. Since sapphyrins bind 
phosphate, K=20 M' in water at pH 7, the linked 
texaphyrin-sapphyrin complex (txp-sap) could effectively 
increase the metal concentration at locations adjacent to the 
sapphyrin binding sites. Since the txp-sap molecule would 
be quite large, it is expected that the ternary structure of 
RNA will provide a limited number of favorable binding 
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sites. Thus, a degree of structural selectivity for RNA 
hydrolysis would be expected, with this selectivity being 
based on the conformations of the substrate molecules. 
The synthesis of (Eu) texaphyrin-sapphyrin conjugate 
Synthesis was accomplished by amide bond formation 
between activated (Eu)texaphyrin carboxylic acid and 
amino-substituted sapphyrin. By the same strategy, a variety 
of texaphyrin-sapphyrin conjugates may be prepared includ 
ing conjugates where other metallic cations may be incor 
porated into the texaphyrin moiety, as well as conjugates of 
texaphyrins with ligands other than sapphyrin. The forma 
tion of exemplary amide-linked derivatives of texaphyrin is 
illustrated below, R=sapphyrin, texaphyrin, porphyrin, a 
catalytic group, or amine-containing substituents such as 
amine-containing saccharides, polysaccharides, amino 
acids, amino acid derivatives, polyamino acids and the like; 
n=1-7; (NH2) represents monoamines NH2(CH), 
x=0-12; diamines NH2-(CH2)-NH2 x=2-12; triamines 
(NH2(CH4).),N, x=2-6; or tetra (NH(CH.).)N(CH2)N( 




The synthesis of (Eu) texaphyrin acid EuT2B1 (O(CH) 
COH) ((16 R=(CH)OH, M=Eu(III), n=3)). The corre 
sponding nonaromatic texaphyrin macrocycle.HCl (0.694g, 
1 mmol) was dissolved in 80 mL of dry methanol. 
Eu(OAc).HO (0.329 g, 1 mmol) was added, followed by 
triethylamine (0.5 mL). The reaction mixture was refluxed 
(reflux condenser was open to the air) for 6 hours, with the 
progress of metallation followed by visible spectra. Metha 
nol was evaporated under reduced pressure to give a dry, 
dark solid which was washed with dichloromethane under 
vigorous stirring for 2 hours. The product was filtered off, 





with zeolite (by standard procedure for removing free 
europium salt). The product was twice precipitated from 
methanol by adding diethylether. The collected dark green 
solid was dried under high vacuum overnight. Yield 91.0%. 
Characterization data: Elemental analysis for 
CHNOEu.2(OAc) (F.W. 920.855) calc. 54.78% C, 
5.47% H, 7.61% N; found 54.46% C, 5.50% H 7.55% N. 
FAB HRMS: For CHNOEu calc. 802.24626; found 
802.247752. UV-Vis (EtOH, ): 420, 469, 760 nm. 
The Synthesis of EuTexaphyrin-Sapphyrin derivative 
((16c, R=(CH2)3OH, M=Eu(III), n=3)): The aminosapphy 
rin derivative 3.8.17.22-tetraethyl-12-N-(2-aminoethyl) 
aminocarbonylethyl-2.7.13.18,23-pentamethylsapphyrin 
(16) was prepared as follows: The corresponding sapphyrin 
monocarboxylic acid was, after activation with DCC. 
reacted with t-BOC monoprotected ethylenediamine and 
then subsequently deprotected by treating with TFA at room . 
temperature for 1 hour. 
Texaphyrin 16 (0.092 g. 0.1 mmol) was dissolved in 10 





dimethylamine), and the solution was cooled on ice to 0°C. 
The activating agent (carbodiimide. EDC, 95.5 mg 0.5 
mmol) and hydroxybenzotriazole (5 mg) were added and the 
mixture was held at 0° C. for 45 minutes. The solution of 
aminosapphyrin derivative 16 (0.067 g., 0.1 mmol) in 5 mL 
of dimethylformamide and 0.1 mL of dry pyridine was 
added at the same temperature. The reaction mixture was 
kept at 0° C. for 30 minutes, allowed to warm to room 
temperature, and stirred for 3 days. Solvent was evaporated 
under reduced pressure. The crude product was washed, 
dissolved in EtOH (10 mL), and diethylether was slowly 




Characterization data: UV-Vis (EtOH): 358, 431,450, 
618,681.761 nm (H.O, pH7): 358.408,455, 623,675,765 





Alternative synthetic approaches to analogous het 
erodimers may include the coupling of amino-substituted 
texaphyrins (prepared by the reaction of texaphyrin car 
boxylate anion with monoprotected ethylenediamine HN 
(CH)NHR, where R is (CH)COCO-(t-BOC), followed 
by heating to 180° C. to effect deprotection)) with activated 
sapphyrin monocarboxylic acid derivatives (e.g., sapphyrin 
acid chloride, or the products obtained from treatment with 
dicylohexylcarbodiimide, DCC) 
Compound 16 was tested (a) for transport of ADP and 
ATP across bulk liquid membrane-efficient transport at 
neutral pH was observed, and (b) for phosphodiester 
hydrolysis-during ATP transport, AMP was formed as a 
result of hydrolysis. Transport studies were performed using 





type model membrane system (Araki et al., 1990). Aqueous 
phase I (source phase) was 5 mM solution of ADP, ATP at 
pH 7.0, the organic phase was 0.1 mmol solution of (Eu) 
texaphyrin-sapphyrin conjugate 16. Aqueous phase II 
(receiving phase) was water, pH 7.0. The increase in con 
centration of ADP and ATP in the receiving phase as a result 
of membrane transport was followed as a function of time. 
Quantities transported were determined by HPLC analysis 
of receiving phase using cytosine and/or adenosine as the 
internal standard(s) (reverse phase analytical column, 10 
mM phosphate buffer, pH 5.6). In this way the initial 
transport rates for the through-membrane transport of ADP 
and ATP were derived. Results showed that the initial rate of 
transport for ADP is in the range of 5x10 mol/cmhr, and 
about five times lower than this for ATP. During the course 
of the above-described through-membrane transport of ADP 
and ATP the formation of a new compound in the receiving 
phase, determined to be AMP by comparison with an authen 





not present in the source phase nor observed when carrier 
free control experiments were carried out. its production as 
the result of the (Eu) texaphyrin-sapphyrin conjugate medi 
ated transport process is taken as indicating that the conju 
gate is capable of effecting the hydrolysis of a phosphoric 
anhydride bond. 
Texaphyrin-sapphyrin conjugates or analogs thereof 
should be very useful in antisense applications: Sapphyrin 
binds to phosphate diesters, such as those of DNA, with high 
specificity and affinity. Certain metallotexaphyrin com 
plexes bind to anionic phosphates and effect the hydrolytic 
cleavage of RNA and related species. Thus, a texaphyrin 
Sapphyrin conjugate should provide an enhanced recogni 
tion of RNA/DNA and an improved rate of hydrolysis by 
virtue of the induced "neighboring group effect". 
Along with the potential to cleave RNA specifically, the 
texaphyrin molecule may be designed to pass through cell 
membranes and selectively attack viral RNA. Such a mol 
ecule would have the potential to treat human patients 
infected with a variety of viruses, including HTV, and to treat 
blood in vitro or ex vivo for viral infection to purge or purify 
blood. 
EXAMPLE 10 
Further Uses for Texaphyrin-Metal Complexes 
Coupled to Site-Directed Molecules 
Many cell membranes are partially constructed from 
phospholipids. Thus, metallotexaphyrin complexes may be 
developed into synthetic specific phospholipases. One 
skilled in the artin light of the present disclosure could then 
determine precisely the lipid side chain that is connected via 
the phosphate ester bond in a given phospholipid. An 
extension of this process would be to digest cell membrane 
components such as phosphatidyl choline and sphingomy 
elin. This is important since the latter participates in nerve 
and brain functions. 
The present invention may be developed into a probe, a 
reagent or an assay for in vitro use in the detection, char 
acterization or quantitation of a specific RNA sequence or of 
other phosphate-containing molecules. 
The development of potent cytotoxins from metallotexa 
phyrin complexes may be accomplished by developing 
reagents that specifically hydrolyze phosphoric anhydrides 
such as ATP. ADP, NADH, or FADH. These cytotoxins may 
disrupt, in a biologically specific way, the flow of free 
energy in the cell and essentially starve the organism. This 
could allow for the death of undesired plants and animals or 
the treatment of mammalian cancers. 
Liver diseases causing the accumulation of glycogen may 
be treated by hydrolyzing uridine diphosphate glucose 
(UDP), the phosphodiester precursor to glycogen. The 
present invention demonstrates that uridine phosphates are 
hydrolytically cleaved by metallotexaphyrin complexes and 
previous work with metallotexaphyrins (U.S. Pat. No. 5.252, 
720) has shown that they localize in the liver. Thus, one 
skilled in the art would realize that the basic features of this 
approach have already been demonstrated by experiment. 
Cyclic adenosine monophosphate (cAMP) is believed to 
play an important part in regulating various hormones. 
Hydrolyzing cAMP to the linear adenosine monophosphate 
(AMP) impedes certain hormone regulation. Texaphyrin 
complexes may therefore be used as hormone regulation 
drugs. 
A further use for metallotexaphyrin complexes may be as 












phosphate esters. Alkyl phosphate esters have a wide range 
of uses including solvents in chemical reactions, insecticides 
(e.g., parathion) and chemical nerve gases (e.g. diisopropyl 
phosphofluoridate. DIPF). Hydrolysis and detoxification of 
these agents in the environment is often slow by natural 
processes. Developing catalysts for the hydrolysis of alkyl 
phosphate esters could greatly improve the lives of many 
people. Texaphyrin complexes could further be developed as 
treatment for patients that have been exposed to such nerve 
agents. 
The following references are incorporated in pertinent 
part by reference herein. 
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U.S. Pat. No. 5,120,411. various modifications in light thereof will be suggested to 
U.S. Pat. No. 5,041,078. persons skilled in the art and are to be included within the 
Wickstrom. E. Ed. Prospects for Antisense Nucleic Acid spirit and purview of this application and scope of the 
Therapy of Cancer and AIDS, Wiley-Liss, NY. 1991. appended claims. 
It is understood that the examples and embodiments 5 
described herein are for illustrative purposes only and that 
SEQUENCE LISTING 
( 1) GENERAL INFORMATION: 
( i i i ) NUMBER OF SEQUENCES: 18 
( 2) INFORMATION FOR SEQID NO:1: 
( i y SEQUENCE CHARACTERISTICs: 
( A LENGTH: 20 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
( D TOPOLOGY: inear 
( i i y MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "DNA" 
( x i ) SEQUENCE DESCRIPTION: SEQID No:1: 
C T C G GC CATA G C GAA T G TT C 20 
(2) INFORMATION FOR SEQID NO:2: 
( i y SEQUENCE CHARACTERISTICs: 
(A) LENGTH:20 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i y MOLECULE TYPE: other nucleic acid 
(A) DESCRIPTION: fidesc = "DNA" 
( x i ) SEQUENCE DESCRIPTION: SEQID NO:2: 
C T C C T G T GAG CCG G G T G TT G 2 O 
( 2) INFORMATION FOR SEQID No.3: 
( i ) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 30 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULE TYPE: other nucleic acid 
(A) DESCRIPTION: desc = "RNA" 
( x i ) SEQUENCE DESCRIPTION: SEQID NO:3: 
CA CUGUA GAA GA G C C G GUAU C G CUUA CAAG 30 
( 2) INFORMATION FOR SEQID No:4: 
{ i ) SEQUENCE CHARACTERISTICS: 
(A) LENGTH:20 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(d) TOPOLOGY: linear 
( i i ) MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "TDNA" 
( xi ) SEQUENCE DESCRIPTION: SEQID No:4: 




( 2 INFORMATION FOR SEQID NO:5: 
( i SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 12 base pairs 
B ) TYPE; nucleic acid 
( C ) STRANDEDNESS: single 
( D.) TOPOLOGY: linear 
( i i ) MOLECULE TYPE: other nucleic acid 
A DESCRIPTION: desc = "DNA" 
( xi ) SEQUENCE DESCRIPTON: SEQID NO;5: 
C T C G GC CATA GC 2 
( 2 INFORMATION FOR SEQID NO:6: 
( i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 9 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULE TYPE: other nucleic acid 
( A DESCRIPTION: desc = "DNA" 
( xi ) SEQUENCE DESCRIPTION: SEQID NO:6: 
CT CG GC CAT 9 
( 2 INFORMATION FOR SEQED NO:7: 
( i SEQUENCE CHARACTERISTICS: 
( A LENGTH: 12 base pairs 
(B) TYPE: nucleic acid 
( C STRANDEDNESS: single 
(D) TOPOLOGY: linear 
{ i i y MOLECULETYPE: other mucleic acid 
( A DESCRIPTION: ?ciesc = "DNA" 
( xi ) SEQUENCE DESCRIPTION: SEQID NO:7: 
ATA G CGA T G T T C 2 
( 2) INFORMATION FOR SEQID NO:8: 
( i SEQUENCE CHARACTERISTICS: 
( A LENGTH: 29 base pairs 
B TYPE: mucleic acid 
( C ), STRANDEDNESS: single 
( D TOPOLOGY: linear 
( i i ) MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "RNA" 
( x i ) SEQUENCE DESCRIPTION: SEQID NO:8: 
CA CUUA GAA GA G C C C GUAU C G COACA AG 9 
( 2 INFORMATION FOR SEQID NO:9: 
( i SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 10 base pairs 
(B) TYPE: nucleic acid 
(c) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i MOLECULE TYPE: other nucleic acid 
(A) DESCRIPTION: desc = "DNA" 
( i SEQUENCE DESCRIPTION: SEQID NO:9: 




( 2 INFORMATION FOR SEQID NO:10: 
( ; ) SEQUENCE CHARACTERISTICs: 
( A LENGTH: 12 base pairs 
(B) TYPE: nucleic acid 
C). SRANDEDNESS: single 
DOPOLOGY: linear 
( i i ) MOLECULETYPE; other nucleic acid 
(A) DESCRIPTION: desc = "DNA" 
( x i ) SEQUENCE DESCRIPTION: SEQID No:10: 
TAG C GAA T G TC 1 2 
( 2) INFORMATION FOR SEQID NO:11: 
( i ) SEQUENCE CHARACTERISTICS: 
( A LENGTH: 36 base pairs 
( B, ) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "RNA" 
( x i ) SEQUENCE DESCRIPTION: SEQID NO:11: 
AAAUAAAA C C J C U GAA GUAG ACAC J C G GCC CA CAA C 3 6 
( 2 INFORMATION FOR SEQID No:12: 
( i ). SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 17 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS; single 
{ D ) TOPOLOGY: linear 
i i MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "DNA" 
( x i SEQUENCE DESCRIPTION: SEQID No:12: 
C GT GA C C G T G T 7 
( 2) INFORMATION FOR SEQID NO:13; 
{ i SEQUENCE CHARACTERISTICs: 
( A LENGTH: 16 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
( D.) TOPOLOGY: linear 
( i i ) MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "TNA" 
( x i ) SEQUENCE DESCRIPTION: SEQID NO:13: 
TTTA TT G G A GACT 1 6 
( 2 INFORMATION FOR SEQID No:14: 
( i) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 16 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
i i MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "DNA" 
( x i SEQUENCE DESCRIPTION: SEQID No:14: 
T G T G A C C C G T G T 6 
5,763,172 
-continued 
( 2) INFORMATION FOR SEQID No:15: 
( i ) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 18 base pairs 
(B) TYPE: nucleic acid 
( C ), STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: /desc = "DNA" 
( x i SEQUENCE DESCRIPTION: SEQID NO:15: 
T C T G T GAG C C G G G T G T G 1 8 
( 2) INFORMATION FOR SEQID No:16: 
( i SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 19 base pairs 
(B) TYPE: nucleic acid 
( C STRANDEDNESS: single 
D.) TOPOLOGY: linear 
( i i y MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: desc = "TNA" 
( x i ) SEQUENCE DESCRIPTION: SEQD NO:16: 
A T C E G T G A G C C G G G T G 9 
( 2 INFORMATION FOR SEQID No:17: 
( i ) SEQUENCE CHARACTERISTICS: 
(A) LENGTH: 15 base pairs 
(B) TYPE: nucleic acid 
(C) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: other nucleic acid 
(A) DESCRIPTION: /desc = "DNA" 
( x i ) SEQUENCE DESCRIPTION: SEQED NO:17: 
GAGCC T C C T G GT TTT 15 
( 2) INFORMATION FOR SEQID NO:18: 
( i y SEQUENCE CHARACTERISTICs: 
(A) LENGTH: 15 base pairs 
(B) TYPE: nucleic acid 
( C STRANDEDNESS: single 
( D TOPOLOGY: linear 
( i i ) MOLECULETYPE: other nucleic acid 
( A DESCRIPTION: desc = "DNA" 
( xi ) SEQUENCE DESCRIPTION: SEQID NO:18: 
CAT C T G T G A G CCG G G 15 
What is claimed is: 55 2. A method for enhancing the therapeutic activity of an 
1. A method for enhancing the therapeutic activity of an 
oligonucleotide in a cell, the method comprising: 
contacting a targeted intracellular RNA in a cell with a 
metallotexaphyrin-oligonucleotide conjugate, the con 
tact being under physiologic conditions and for a time 
sufficient to hydrolyze the phosphate ester bond of said 
targeted intracellular RNA, wherein the metallotexa 
phyrin of said metallotexaphyrin-oligonucleotide con 
jugate has catalytic activity for phosphate ester bond 
hydrolysis and the oligonucleotide of said 
metallotexaphyrin-oligonucleotide conjugate has 
complementary binding affinity to said targeted intra 
cellular RNA. 
65 
oligonucleotide in a cell, the method comprising: 
contacting a targeted intracellular RNA in a cell with a 
metallotexaphyrin-oligonucleotide conjugate, the con 
tact being under physiologic conditions and for a time 
sufficient to hydrolyze the phosphate ester bond of said 
targeted intracellular RNA, wherein the metallotexa 
phyrin of said metallotexaphyrin-oligonucleotide con 
jugate has catalytic activity for phosphate ester bond 
hydrolysis and the oligonucleotide of said 
metallotexaphyrin-oligonucleotide conjugate has 




where the metallotexaphyrin-oligonucleotide conjugate 
has the following structure: 
M is a divalent or a trivalent metal cation catalyzing 
phosphate ester bond hydrolysis in aqueous solution; 
R-R. R. and Rs are independently hydrogen, halide, 
hydroxyl, alkyl, aryl, haloalkyl, nitro, formyl, acyl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, saccharide, 
carboxy, carboxyalkyl, carboxyamide. 
carboxyamidealkyl, aminoalkyl, sulfonatoalkyl. 
amidealkyl, aryl, a site-directed molecule. a catalytic 
group. or a couple to a site-directed molecule or to a 
catalytic group; 
R and R are independently selected from the groups of 
R-R. R. and Rs, with the proviso that the halide is 
other than iodide and the haloalkyl is other than 
iodoalkyl; 
Rs and Ro-R2 are independently hydrogen, alkyl, aryl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl. 
carboxyalkyl, carboxyamidealkyl or a couple to a sac 
charide to a site-directed molecule or to a catalytic 
group; and 
Z is less than or equal to 5; 
where at least one of R-R is a site-directed molecule or 
a couple to a site-directed molecule, and the site-directed 
molecule is an oligonucleotide having binding affinity to 
said targeted intracellular RNA. 
3. The method of claim 2 wherein the catalytic group is 
inidazole, guanidine, an amino acid, an amino acid 
derivative, a polyamino acid, an amine-substituted saccha 
ride or a metallotexaphyrin complex. 
4. The method of claim 2 wherein the site-directed 
molecule is an oligonucleotide, a hormone, an antibody, a 
molecule having affinity for a biological receptor, or a 
sapphyrin molecule. 
5. The method of claim 2 wherein the oligonucleotide is 
an oligodeoxyribonucleotide. 
6. The method of claim 2 wherein the oligonucleotide is 
further conjugated to a catalytic group. 
7. The method of claim 6 wherein the catalytic group is 
imidazole, guanidine, an amino acid, an amino acid 
derivative, a polyamino acid, an amine-substituted saccha 









8. The method of claim 6 wherein the catalytic group is a 
metallotexaphyrin complex. 
9. The method of claim 2 wherein the oligonucleotide has 
complementary binding affinity for oncogenes. 
10. The method of claim 2 wherein the oligonucleotide 
has complementary binding affinity for the targeted RNA in 
a region proximal to the phosphate ester bond being hydro 
lyzed. 
11. The method of claim 2 wherein the oligonucleotide is 
an antisense oligonucleotide. 
12. The method of claim 2 wherein one of R. R. and Rs. 
is an oligonucleotide or a couple to an oligonucleotide. 
13. The method of claim 2 wherein one of R. R. or Rs 
is O(CH2)CO-oligonucleotide where n is 1-7. 
14. The method of claim 2 wherein M is a lanthanide 
cation. 
15. The method of claim 2 wherein M is Eu(III). Tb(III) 
or Dy(III). 
16. The method of claim 2 wherein the targeted RNA is 
selected from the group consisting of viral, including 
retroviral, RNA; messenger RNA (mRNA); ribosomal 
RNA, RNA cofactors; transfer RNA; small nuclear RNA; 
and small cytoplasmic RNA. 
17. The method of claim 2 wherein the targeted RNA is 
mRNA 
18. The method of claim 2 where the oligonucleotide is an 
oligoribonucleotide. 
19. The method of claim 2 where the oligonucleotide is a 
derivatized oligonucleotide or an oligonucleotide analog. 
20. The method of claim 2 where the oligonucleotide is a 
derivatized oligonucleotide and is selected from the group 
consisting of methylphosphonates, phosphotriesters, 
phosphorothioates, and phosphoramidates. 
21. The method of claim 2 where the oligonucleotide is 
2'-O-alkyl oligoribonucleotide. 
22. The method of claim 2 where R is CHCH or 
CHCH2CH2OH; each of RandR is CHCH; R is CH: 
each of R. R. and R-R is H.; R is H, CH, OCH 
O(CH),COOH, OCHCHCH-OH or O(CHCHO), CH, 
where n is 1-7; and Rs is an oligonucleotide or a couple to 
an oligonucleotide. 
23. The method of claim 22 where R is O(CH2)CO 
oligonucleotide where n is 1-7. 
24. The method of claim 2 where M is a lanthanide metal 
cation; R is CHCH or CHCHCH-OH; each of R and 
R is CHCH; R is CH; each of R. R. and R-R is H 
R is H. CH, OCH, O(CH.)COOH, OCHCHCH-OH or 
O(CH-CHO)CH where n is 1-7; and Rs is an oligonucle 
otide or a couple to an oligonucleotide. 
25. The method of claim 24 where R is O(CH2)CO 
oligonucleotide where n is 1-7. 
26. The method of claim 24 where the targeted RNA is 
mRNA. 
27. The method of claim 24 where the oligonucleotide is 
an antisense oligonucleotide. 
28. The method of claim 2 where M is Y(III). 
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